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Abstract
Estrogen fulfills a variety of physiological roles
through its nuclear receptors, estrogen receptors (ERs).
The action of ERs is modulated and mediated by diverse
interacting cofactors. The initial aim of this thesis
work was to identify ligand-, subtype- and/or cell typespecific ER-interacting proteins.
I identified a number of nuclear extract-derived
proteins that interact with immobilized ER ligand binding
domains (LBDs) in a 17(3-estradiol (E2)-dependent manner.
The most prominent of these are components of the thyroid
hormone receptor associated protein (TRAP)/Mediator
coactivator complex, which interacts with ERa and ER(3
both in unfractionated nuclear extracts and in purified
form equally efficiently. Although some of other
interacting proteins displayed subtype specificity, the
main focus of the work was to characterize the function
of TRAP/Mediator in ER-dependent transcription for both
ERa and ER(3.
Studies with extracts from TRAP220-/- mouse embryo
fibroblasts (MEFs) revealed that the interactions between
TRAP and ERs are dependent on TRAP22 0, a TRAP/Mediator
subunit previously shown to interact with ER and other
nuclear receptors in a ligand-dependent manner. The

physiological relevance of the in vitro interaction was
further documented by the isolation of an ERaTRAP/Mediator complex from HeLa cells expressing an
epitope-tagged ERa lacking AB domain (f:ERa,AAB). Most
importantly, the complete TRAP/Mediator complex was shown
to directly enhance ER function in a highly purified cell
free transcription system.
I further examined the roles for TRAP2 2 0 NR box in
ER-TRAP/Mediator interaction. Both NR boxes were found to
be important for ER-TRAP/Mediator interaction. Transient
transfection assays with TRAP220-/- MEFs revealed that
the absence of TRAP220 or mutations in either or both NR
boxes attenuated modestly ER dependent transcription in
TRAP220-/- MEFs. This indicated that TRAP220 and its NR
boxes are required for the optimal transcrictipationl
activity of ER. However, the observation of the
significant E2 responses in TRAP220-/- MEFs suggested the
existence of alternative pathways for E2 responses
different from TRA/Mediator or the absence of natural
constraints that impose a requirement for TRAP220 to
overcome. Similarly, cell-free transcription assays also
showed modest defect in function of TRAP/Mediator for ER
dependent transcription when TRAP/Mediator contains
TRAP2 2 0 NR mutants.

Chapter
Introduction

1

1.1. Estrogen Receptor

The transduction of extracellular signals into
intracellular responses is a vital and fundamental
process of all living organisms. It is the means by which
communication between the genetic attributes of an
organism and surrounding nature takes place. Through this
system, the living organism can achieve active adaptation
to their surroundings resulting in long-term evolutionary
process. One major system of communication that has
evolved in higher eukaryotes is the endocrine system,
which is coordinated by chemical messengers called
hormones. Hormones influence the actions of many tissues
and thus affect many processes including metabolism,
growth, development, emotion, and behavior, in addition
to contributing to homeostasis (Goodman, 1996a). The
steroid hormone, estrogen, is considered a female sex
steroid hormone because it is produced mainly from the
ovary and controls the growth, differentiation, and
function of female reproductive and accessory sex tissues
(Goodman, 1996b). However, estrogen also influences male
reproductive and accessory sex tissues (Luconi et al.,
2002). In addition to the reproductive tissues, nonreproductive tissues are also targets of estrogen. These

include skin, hair, bone, liver, pituitary,

hypothalamus,

cardiovascular system and behavioral centers in the brain
(Farhat et al., 1996; Oursler, 1998; Toran-Allerand et
al., 1999; Shupnik, 2002; McEwen, 2002).
How does estrogen affect target tissues? Cells
appear to have evolved two ways to respond to estrogen
signals. These are termed the genomic and nongenomic
responses. First, the classical genomic action of
estrogen is mediated through nuclear receptors called
estrogen receptors (ERs) of the target cells by
regulating the expression of specific subsets of genes
that lead to long-term physiological effects. On the
other hand, the nongenomic action of estrogen involves
mechanisms that are not necessarily mediated through
changes in gene expression. Instead, they are thought to
be mediated through interactions between estrogen and
cellular membrane components such as lipids and/or
possible membrane receptors (McEwen and Alves, 1999;
Watson and Gametchu, 1999). There are reports suggesting
the existence of novel membrane receptors that are
distinct from ERs and their involvement in these effects
(Luconi et al., 2001; Nadal et al., 2000). However, a
number of studies have provided evidence that a
subpopulation of ERs are present in the cellular membrane

and play important roles in these rapid responses through
intracellular signaling (Levin, 2002; Razandi et al.,
1999). This has suggested that ERs are the primary
mediator of estrogen actions in both the genomic and the
nongenomic pathways.

1.1.1. ER is a member of nuclear hormone receptor family.
Two subtypes of ER have been identified so far: the
classical ERa (Green et al., 1986; Greene et al., 1986)
and the recently discovered ER|3 (Kuiper et al., 1996). ERs
are members of a large superfamily of nuclear receptors
that function as ligand-regulated transcription
activators. Like other nuclear receptors, ERs are modular
proteins consisting of an amino-terminal region (A/B
domain); a central DNA binding region (C domain); the
carboxyl-terminal region (E domain) which is responsible
for ligand-binding; the hinge region (domain D), which is
located between the DNA and the ligand-binding domains;
and the F domain, which is located at the extreme
carboxyl terminus of the protein (reviewed in Gronemeyer,
1991) .
ERs contain two transcriptional activation functions
(AFs), which are responsible for the expression of target
genes; the ligand-independent, amino-terminal AF-1 and

the ligand-inducible, carboxyl-terminal AF-2 (Tora et
al., 1989). Both AF-1 and AF-2 are required to achieve
maximal transcriptional activity of ER (Tzukerman et al.,
1994) through the cooperative action (Chen et al., 2000;
Kobayashi et al., 2000) but can also function
independently with certain cell type and promoter
specificities (Tzukerman et al., 1994). In particular,
AF-1 activity exhibits cell type and promoter context
specificities (Berry et al., 1990; Tora et al., 1989),
displays different potency in each ER subtype (Hall and
McDonnell, 1999; Mclnerney et al., 1998) and is regulated
via phosphorylation cascades (Kato et al., 1995) by
facilitating recruitment of cofactors (Tremblay et al.,
1999). To date, a wide array of factors have been shown
to interact with and enhance transcriptional activities
of ERs. A large subset of these factors interact directly
with the ER-LBD in a ligand and AF-2 dependent manner. As
shown in three dimensional structures, upon ligand
binding receptor undergoes conformational changes in the
orientation of helix H12 within core AF-2 in order to
allow cofactors to interact (reviewed in Pike et al.,
2000).

1.1.2. Physiological roles of ER

The recent development of estrogen receptor knockout
(ERKO) mice has provided suitable models to study the
physiological roles of ERs (Couse and Korach, 1999;
Mueller and Korach, 2001; Nilsson and Gustafsson, 2002)
As expected, the phenotypes exhibited in ERa knockout
(referred as aERKO) mice due to estrogen insensitivity
have demonstrated significant roles of ERa in the
reproductive system and accessory sex tissues (Couse and
Korach, 1999). These include functions: (1) in
proliferation and differentiation of cells that are
critical to the function of the adult female reproductive
tract and mammary gland; (2) as an essential component in
growth factor signaling in the uterus and mammary gland;
(3) in negative regulation of gonadotropin gene
transcription and LH levels in the hypothalamic-pituitary
axis; (4) as a positive regulator of progesterone
receptor (PR) expression in several tissues; (5) in the
positive regulation of prolactin (PRL) synthesis and
secretion from the pituitary; (6) as a promotional factor
in oncogene-induced mammary neoplasia; and (7) as a
crucial component in the differentiation and activation
of several behaviors in both female and male (Couse and
Korach, 1999). Genetic ablation of ERa also revealed
essential roles for ERa in certain aspects of male

reproduction, as reflected in phenotypes displayed in
aERKO male mice such as production of abnormal sperm and
the loss of intromission and ejaculatory response (Couse
and Korach, 1999). Moreover, the phenotypes observed in
aERKO mice have indicated more diverse roles of ERa in
various nonreproductive tissues such as bone, brain and
cardiovascular system (Mueller and Korach, 2001; Nilsson
and Gustafsson, 2002). These aberrant phenotypes
included: (1) growth arrest of longitudinal bones in both
sexes as well as lower bone density in male mice, (2)
increased aggression and infanticide in female mice as
well as reduced aggression in male mice, (3) reduction of
estradiol-induced angiogenesis and increase in serum
apolipoprotein E, lower basal levels of vascular nitric
oxide, increase in calcium channels and delayed cardiac
depolarization (Couse and Korach, 1999). However, certain
estrogen pathways in the aERKO female appear intact or
unaffected, such as the ability of the uterus to
successfully exhibit a progesterone-induced
decidualization response, and the possible maintenance of
an LH surge system in the hypothalamus including the
proliferative and differentiative actions critical to the
function of the adult female reproductive tract and
mammary gland (Couse and Korach, 1999).

Compared to aERKO mice, ER{3 knockout

((3ERK0) mice

showed mostly normal phenotypes in both female and male
mice, except for subfertility in female mice that may be
due to infrequent and inefficient ovulation (Krege et
al., 1998). This suggested that ER(3 is essential for
normal ovulation efficiency but not for female or male
sexual differentiation, fertility, lactation or certain
other nonreproductive system (Krege et al., 1998). Loss
of both receptors in the double ERKO (DERKO) mice leads
to a striking sex reversal phenotype characterized by
postnatal loss of oocytes and redifferentiation of the
remaining somatic cells to Sertoli-like cells (Couse et
al., 1999). This surprising ovarian phenotype of DERKO
mice is distinct from that of the individual ERKO mice
(Couse et al., 1999). This indicates cooperative actions
of both receptors that are required for the maintenance
of germ and somatic cells in the postnatal ovary (Couse
et al., 1999). Analyses of the phenotypes of aERKO, (3ERK0
and DERKO mice suggested specific contribution of each
subtype of ERs as well as cooperative actions of both ERs
in estrogen signaling (Couse et al., 1999).

1.1.3. Actions of ER

10

What is the molecular basis of the above-mentioned
physiological effects? What is the molecular mechanism of
ER action that mediates estrogen signaling? This has been
one of the most intensively studied subjects due to its
clinical and pharmaceutical relevance. Long lasting
clinical needs for novel hormone replacement therapies
that retain the beneficial effects of estrogen, and at
the same time do not possess the higher risk of breast
cancer has driven the pharmaceutical industry to develop
new Selective Estrogen Receptor Modulators (SERMs) that
modulate ER in a tissue-selective manner. With respect to
this, it is very important to understand the molecular
mechanism of ER action underlying the behavior of SERMs.

1.1.3.1. Genomic actions of ER
The genomic actions of ERs have been well
established. As ligand-modulated, DNA-binding
transcription factors, ERs regulate expression of their
target genes upon ligand binding. The process of genomic
action of ER, thus, can be dissected into four major
components, which together contribute to the modulation
of ER function: ligands, DNA, ER and cellular factors.

1) Ligands

11

Todate thousands of ligands for ERs have been
synthesized. These compounds can be classified into
agonist, partial agonist (partial antagonist) and pure
antagonist depending on the ER response to these ligands.
Early studies using protease digestion assays
suggested that ligand binding induced a conformational
rearrangement in the ligand binding domain (LBD) and
hinted that the structure of ER-ligand complex might
contribute to its functional specificity (McDonnell et
al., 1995). Recent crystallographic analyses confirmed
this idea by showing that different functional classes of
ligands induce distinct conformations of ER in the
orientation of helix H12 (reviewed in Pike et al., 2000).
Agonist and antagonist bind at the same site within the
core of the LBD but demonstrate different binding modes
(Brzozowski et al., 1997; Pike et al., 1999; Shiau et
al., 1998). In the case of agonists such as estradiol
(E2) and diethylstilbestrol (DES), the ligand is
completely encased within the ligand-binding pocket and
helix H12 is aligned over the pocket (Brzozowski et al.,
1997; Shiau et al., 1998). This conformation allows
peptides containing the short signature sequence motif
(LXXLL motif where L is Leucine and X is any amino acid)
known as the NR box to interact with the static region of

12

the coactivator recognition groove in AF-2 domain
(Brzozowski et al., 1997; Shiau et al., 1998). The
binding of the partial antagonists, tamoxifen (TAM) and
raloxifene (RAL), however, is accompanied by major
structural reorganization in the ternary structure in
both ERs (Brzozowski et al., 1997; Pike et al., 1999;
Shiau et al., 1998). The bulky side chain of the ligands
protrudes out of the ligand-binding pocket. The resulting
steric clashes (1) inhibit helix H12 from covering the
ligand-binding pocket and instead, (2) force helix H12 to
extend to the coactivator recognition groove, thereby
imitating the interactions of ER with the NR box through
its NR-box like sequence (LXXML where L is Leucine, X is
any amino acid, and M is Methionine) (Shiau et al.,
1998). The structure of the ER|3 LBD bound to the ER(3
partial agonist, genistein (GEN), reveals that ligand
binding can stabilize yet another conformation of H12
(Pike et al., 1999). In this complex, H12 is bound over
the ligand-binding pocket in a position such that it
occludes the coactivator recognition groove partially
(Pike et al., 1999). However, the functional significance
of this conformation of the LBD is unclear (Pike et al.,
1999). The side chain of ICI 164,384, a pure antagonist,
binds directly to the coactivator binding cleft of ER(3,

13

causing physical blockade of H12 alignment

(Pike et al.,

2001). Complete destabilization of H12 configuration and
concomitant exposure of a large hydrophobic patch on the
surface of ER-LBD is thought to be an account for rapid
degradation of ICI-bound ER and such degradation is
considered as a major mechanism of pure antagonism (Pike
et al., 2001) .

2) DNA
As a template, DNA provides the genetic information
for transcription. DNA also supplies its own regulatory
information through gene-specific combinatorial
arrangement of enhancer elements recruiting cognate
sequence-specific DNA-binding transcription activators
and distinct architecture of the core promoter. In this
way, DNA is the key component to impose unique
specificity to expression of a given gene. Consistent
with this notion, DNA participates in important aspect(s)
of regulation of ER function.
Comparison of the promoter sequences of estrogenresponsive genes led to the identification of the
consensus estrogen response element (ERE), a palindrome
of PuGGTCA motifs separated by 3 bp (Evans, 1988; Green
and Chambon, 1988). ER interacts with DNA as dimers, with
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one receptor interacting with each sequence motif
(Gronemeyer and Meyer, 1991). The sequence-specific
recognition of these elements is through the DNA binding
domain (DBD) region of ER, which consists of two Cys4
zinc fingers (Gronemeyer and Meyer, 1991). Mutation and
crystallographic analyses revealed the molecular
determinants dictating the sequence specificity of
interactions between ERs and specific DNA elements
(Danielsen et al., 1989; Mader et al., 1989; Umesono and
Evans, 1989).
The composition of the consensus sequence and the
spatial organization of the motifs together with flanking
sequences are important for the affinity and the
specificity of ER binding. Although a few promoters of
estrogen target genes contain EREs that match the
consensus sequence (Xenopus Vitellogenin A2, human EFP,
human EBAG9) (Ikeda et al., 2000; Inoue et al., 1993;
Klein-Hitpass et al., 1986), most elements identified to
date are not perfectly palindromic (reviewed in Klinge,
2001). Deviations from the consensus in one half-site
reduce ER-binding affinity in vitro (Nardulli et al.,
1996). It is interesting to note that the pS2 and the
cathepsin D promoters, which both contain a T to C
mutation in the PuGGTCA motif, were reported to function
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poorly in endometrial carcinoma Ishikawa cells, but
efficiently in breast carcinoma MCF7 cells (Miralles et
al., 1994). Moreover, it has been suggested that the
individual ERE sequences induce specific conformational
changes in ER (Wood et al., 2001 and references therein).
This ERE-induced allosteric modulation of ER conformation
has been shown to affect the recruitment of specific
coactivator proteins leading to differential gene
expression from target genes containing divergent ERE
sequences (Hall et al., 2002; Wood et al., 2001). These
studies proposed that diversity of ERE sequences would
provide mechanisms to determine the specificity of target
gene activation by ERs.

3) ER
The surprising discovery that ER(3 is encoded by a
gene different from ERa (Kuiper et al., 1996), has
revealed the complexity of ER action and led to the
reevaluation of the mechanism of ER function. ER(3 shows
an overlapping but nonidentical tissue distribution
compared to ERa (Kuiper et al. , 1997). ER(3 is
predominantly expressed in testis, prostate, ovary,
liver, and specific regions of the brain whereas ERa has
been detected in several mouse tissues including the
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mammary gland, uterus, ovary, liver, kidney, heart and
testis (Couse and Korach, 1999). Some tissues, such as
the thyroid gland, epididymis, bone and brain, express
both ERs (Couse and Korach, 1999). However, very few, if
any, of these tissues express both ERs in the same cell
types implying that these receptors have distinct
functional roles in mammals. For example, although rat
ovary contains both ERs, ER(3 is located in the granulosa
cells, whereas ERa is localized to the surrounding thecal
cells (Hiroi et al., 1999; Sar and Welsch, 1999).
In primary structure, human ER(3 displays some
homology to ERa (reviewed in Pettersson and Gustafsson,
2001). The maximal homology between ERa and ER(3 lies in
their DBDs (96% identity) (Ogawa et al., 1998) indicating
that both receptors share the same EREs (reviewed in
Pettersson and Gustafsson, 2001). The LBD is also
relatively conserved (53% identity) between these two
receptors (Ogawa et al., 1998). Consistent with the
primary structural homology, overall similarities in
three dimensional structures of the LBD of both receptors
were demonstrated in crystallographic studies (Pike et
al., 1999; Shiau et al., 2002). Although ERa and ER|3
exhibited similar binding affinities for most ligands
(Kuiper et al., 1997), several new compounds have been
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shown to bind preferentially to specific ER subtypes
(Barkhem et al., 1998; Kuiper et al., 1998). This
observation has led to the recent development of ER(3
selective ligands (Katzenellenbogen et al., 2000; Sun et
al., 1999). The N-terminal domains, namely the A/B
domains of ERa and ER(3, share the least homology (30%
identity)(Ogawa et al., 1998). Considering the
observation that the A/B domain encompasses AF-1, whose
activity acts in cell type- and promoter context-specific
fashions (Berry et al., 1990), the poor homology between
A/B domains of ERa and ER(3 implies that tissue-selective
actions of SERMs could be partly but significantly due to
functional distinction between two subtypes of ERs that
has been attributed to the structural differences between
the A/B domains. Consistent with this idea, ERa contains
a strong AF-1 activity that results in the partial
agonism of some antiestrogens such as TAM and RAL. In
contrast, ER|3 shows, under the same conditions,
negligible AF-1 activity and results in pure antagonism
by TAM and RAL (Mclnerney et al., 1998) . Moreover, ERa
and ER(3 shows opposite responses to the ligands on AP-1
promoters (Paech et al., 1997). In the presence of
estradiol, ERa activates transcription whereas ER(3
represses transcription, but, in the presence of
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antiestrogens, ER(3 is ten times more potent than ERa as
a transcription activator (Paech et al., 1997). This
difference also has been suggested to be a result of the
structural difference between the A/B domains of ERa and
ER(3 (Webb et al. , 1999). The studies reporting the
existence of subtype-specific cofactors (Endoh et al.,
1999; Watanabe et al., 2001; Wu et al., 2001) provided
evidence that these factors interact with ERa AF-1 and
mediate its activity. Taken together, one can speculate
that the different structural features the A/B domains of
ERa and ER(3 contribute to the functional distinction
between ERa and ER(3 through recruitment of different
subset of cofactors.

4) Cellular factors
Lastly, the factors in the cellular environment
contribute significantly to the regulation of ER
function. As transcription factors, ERs communicate with
a wide variety of factors such as gene-specific
components of enhanceosomes, cofactors, chromatin
remodeling factors, and general transcription factors
(GTFs) (Beato and Sanchez-Pacheco, 1996). ERs also
communicate with the components of other signal
transduction pathways (Smith, 1998).
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It is well established that the cellular milieu
changes during the processes of proliferation,
differentiation and/or development. At a given time point
in a certain stage of differentiation and development,
each cell has specific composition of factors depending
on its tissue context. There are many types of tissueand/or stage-specific transcription factors that regulate
cell function (Karin et al., 1990; Maniatis et al., 1987;
Struhl, 1991). Additionally, the existence of tissuespecific transcription cofactors has also been discovered
(Luo et al., 1992; Luo and Roeder, 19 95). At least one
component of general transcription machinery also
displays tissue-dependent variation (Hansen et al.,
1997). Thus, the composition of available factors differs
considerably depending on the cell type and stage of
differentiation. Even in the same cell, each gene obtains
its specificity in transcriptional regulation through
unique combinatorial arrangements of the enhancer
elements, in addition to the individual architecture of
the core promoter. Therefore, ER-mediated transcriptional
activation acquires cell-and/or promoter specificity via
such specific cellular milieu and gene context.

4-1) Transcription factors
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It has been shown that ER functions

indirectly

through protein-protein interactions with other DNAbinding transcription factors. The most studied example
is the ER and activating protein-1 (AP-1) interaction.
Ligand-activated ERa can interact with, and positively
regulate, the collagenase gene promoter by associating
with the AP-1 transcription factor complex within target
cells (Webb et al., 1995). In this particular system,
SERMs, such as TAM, manifest agonist activity. The ER-AP1 activity is particularly strong in endometrium-derived
cell lines, where TAM is an agonist, whereas it is less
active in cultured breast cancer cells, where TAM has
antagonist activity (Webb et al., 1995). This study hints
at a correlation between the ability to activate the
ER—AP-1 complex and the ability of a cell to support the
partial agonist activity of TAM. Moreover, the
observation of the opposite responses of each subtype of
ERs to E2 versus TAM on AP-1 promoters (Paech et al.,
1997) further corroborates the idea of the involvement of
ER-AP-1 complex in tissue specific action of SERMs.
Another well-known example is cooperative action of
ER and Spl. In addition to the above-described ERE sites,
GC boxes (GGGGCGGGG) or GT/CACCC boxes (GGTGTGGGG), which
are binding sites for the transcription factor SP1, were
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found to be associated with individual PuGGTCA motifs in
regulatory regions of an increasingly large number of
estrogen-responsive target genes (reviewed in Safe,
2001). The importance of both the half-ERE and the Spl
site for estrogen response have been indicated by studies
using reporter plasmids containing the cathepsin D
promoter or the RARa promoter. It was shown that
mutations in either the Spl or the half-ERE part of
composite motifs were no longer inducible by estrogen
(Krishnan et al., 1994; Rishi et al., 1995).
Cooperativity between ER and SPl was also observed with
promoters containing palindromic EREs, such as that found
in the vitellogenin Al and the rabbit uteroglobin
promoter (Batistuzzo de Medeiros et al., 1997; Scholz et
al., 1998). However, in some cases ERs may function
cooperatively with Spl activity even without ERE.
Deletion of the PuGGTCA motif in the promoter of the
hsp27 gene did not affect its responsiveness to estrogen
(Porter et al., 1997). Moreover, Spl sites in the
promoters of the c-fos, bcl-2 and IGFBP4 genes were found
to be sufficient for induction by estrogen (Safe, 2001).
Interestingly, the effects of estrogen on Spl activity
exhibited specificity depending on the cell line and the
type of ER expressed. HeLa cells showed no activation of
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Spl by estrogen when ERa was expressed, and a slight
repression with ER(3(Saville et al., 2000). On the other
hand, Spl sites were sufficient for stimulation by ERa
but not ER(3 in MCF7 and MDA-MB-231 breast cancer cells
(Saville et al., 2000). These studies suggested that
ability to support cooperative actions of ER-Spl would be
another possible way of cell type-specific actions of ER.
There are other systems where these indirect
transcriptional regulatory pathways have been shown to be
important. For example, it has been shown in rodents that
the retinoic acid receptor (RAR) promoter is upregulated
both by estrogens and antiestrogens (Elgort et al.,
1996). Remarkably, even the pure antiestrogen ICI 182,780
functions as an agonist on this promoter (Elgort et al.,
1996). Mutational analysis of the RAR promoter revealed
that, in this system, ERa exerts its regulatory
activities in an indirect manner through a pre-bound
transcription factor (Elgort et al., 1996). The identity
of this factor remains to be determined (Elgort et al.,
1996) .
In a different system, antagonist-bound ER
stimulated quinone reductase gene transcription through a
previously defined electrophile-response element (Montano
and Katzenellenbogen, 1997). In this system, ER(3 is a
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more potent activator than ERa through

stronger

interactions with the human homologue of Xenopus gene
which prevents mitotic catastrophe (hPMC2) (Montano et
al., 1998; Montano et al., 2000). These findings
indicated that ERs can contact the transcription
apparatus in an indirect manner through several distinct
types of protein—protein interactions meaning that there
are at least two distinct mechanisms by which the ER can
function as a transcriptional activator in target cells.
There is some evidence, however, that ER, in some
instances, can also function as a transcriptional
repressor through these indirect regulatory pathways. In
bone, for example, it has been shown that estrogens and
antiestrogens effectively suppress production of
interleukin 6 (IL-6), a cytokine required for
osteoclastogenesis and osteoblastogenesis (Girasole et
al., 1992; Jilka et al., 1992; Ray et al., 1994). The
repression of IL-6 expression by ERs in osteoblasts and
bone marrow stromal cells may explain in part the
protective effects of circulating estrogen on bone
density. Upon activation by ligand, the ER physically
interacts with the p65 subunit of nuclear factor B (NFkB), thus blocking its ability to bind to target
sequences located within the regulatory regions of the
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IL-6 genes (Stein and Yang, 1995). In this process, only
regions C to F of ERs are required for NF-kB repression
suggesting that it does not involve ER binding to DNA.
This regulatory paradigm might extend beyond NF-kB, as it
has been shown that the ER can inhibit the
transcriptional activity of CCAAT/enhancer binding
protein (C/EBP) and GATA-1 in a similar way (Blobel et
al., 1995; Stein and Yang, 1995). All together, these
findings strongly support the physiological relevance of
the inhibitory activity of ER.

4-2) Cross-talk with signal transduction pathways
Independent of estrogen signaling, other signal
transduction pathways also regulate the transcriptional
activity of ERs. Treatments with growth factors such as
epidermal growth factor (EGF), insulin, insulin-like
growth factor I (IGF-1), and transforming growth factor
(TGF)-(3 can modulate transcriptional activity of ER
through phosphorylation in the absence of estrogen
(Smith, 1998). Early studies showed that EGF could mimic
effects of estrogen in the mouse reproductive tracts and
pretreatment of mice with the pure anti-estrogen greatly
diminished the uterine response to EGF (Ignar-Trowbridge
et al., 1992) suggesting the ER mediates this effect. The
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lack of uterine response to EGFs in aERKO mice as
described above (Couse and Korach, 1999) further
supported the physiological relevance of EGF signal
transdunction pathway in function of ERa. Typically, such
cross-talk involves the direct phosphorylation of
specific serine residues in AF-1 domains of both ERs by
MAP Kinase (Kato et al., 1995; Tremblay et al., 1999).
The net effect of these phosphorylation events is to
potentiate AF-1 activity by facilitating recruitment of
coactivators to the A/B domain in a ligand-and AF-2independent manner. In the case of ERa, the
phosphorylation on Ser-118 of ERa by MAPK facilitates the
recruitment of another cofactor, p6 8 (Endoh et al.,
1999). Additionally, the phosphorylation of ER(3 by MAPK
resulted in a direct interaction between AF-1 and SRC-1,
independent of ligand and the entire AF-2 sequences
(Tremblay et al., 1999). Such phosphorylation cascades
has been shown to be involved in the TAM-mediated agonism
through modulation of AF-1 or its cofactors (Feng et al.,
2001) .
The observation of E2-mediated downregulation and
TAM-induced upregulation of HER-2/neu (a member of the
EGFR family) synthesis (Newman et al., 2000) suggested
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the existence of a cross-regulatory loop between estrogen
signaling and other signal transduction pathways.

4-3) Cofactors
It is clear from the above-described studies that
the regulatory mechanisms of ER function are diverse and
complex. However, it appears that the regulatory
information provided by distinct ligands, diverse EREs,
different attributes of ER subtypes, differential
cellular ability to support cooperative action with other
transcription factors or signal transduction pathways are
integrated to contribute to the recruitment of cofactors.
This is the hypothesis from which my thesis work has
started (see below). With this view, the dominant effect
of ligands, agonism versus antagonism, depends on the
potential of the ligand to either induce the correct
conformation or disrupt the active conformation or, in
other words, to respectively stimulate or prevent the
correct binding of coactivators.
In support of this idea, a recent report (Shang and
Brown, 2002) provided compelling evidence that the
differential recruitment of cofactors to nonclassical
promoters (such as c-Myc) and/or modulation in cofactor
expression (such as SRC-1) is the primary determinant for
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agonism of TAM in either breast or endometrial cancer
cells. This indicated that cell-type and promoterspecific differences in cofactor expression and/or
recruitment determine the cellular response to SERMs.

1.1.3.2. Nongenomic actions of ER
Estrogen can modulate protein function via
nongenomic actions that are very rapid and cannot be
accounted for by changes in transcription. Increasing
number of studies have indicated that a subpopulation of
ERs located in the cellular membrane play important roles
in these rapid responses through intracellular signaling
(Levin, 2002; Pappas et al., 1995; Razandi et al., 1999).
For example, ERa has been shown to regulate MAP kinase
activity in MCF-7 breast cancer cells through interaction
with the SH2 domain of Src (Migliaccio et al., 1996) and
lead to induction of cell proliferation (Castoria et al.,
1999). ER(3 acts by a similar mechanism in LNCaP prostate
cancer cells (Migliaccio et al., 2000). Modulation of MAP
kinase activity by estrogen has also been described in
bone cells. Kousteni et al demonstrated that the
estrogen-induced antiapoptotic effect is mediated by
activation of Src/Shc/ERK signaling pathway via ER action
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(Kousteni et a l . , 2 0 0 1 ) . Importantly, this study first
provided evidence of the nongenomic effect of ER
dissociated from transcriptional activity of ER by using
synthetic ligands and peptide antagonists (Kousteni et
al., 2001). Estrogen also regulates neuronal excitability
(McEwen and Alves, 1999), intracellular calcium
concentration, cyclic AMP synthesis and phosphoinositide
turnover (reviewed in Kelly and Levin, 2001). Recently,
ERa was shown to interact with the p8 5a regulatory
subunit of the phosphatidylinositol-3-OH (PI3) kinase,
resulting in increased enzymatic activity in vascular
endothelial cells and leading to the activation of
protein kinase B/Akt as well as endothelial nitric oxide
synthase and the release of nitric oxide (Simoncini et
al., 2000). This regulatory pathway may mediate the
cardiovascular protective effects of estrogens, and
appears to be specific to ERa and not ER(3 (Hisamoto et
al., 2001).
These mechanisms of estrogen action also contribute
to gene expression via indirect pathways leading
additional complexity in the regulation. It has been
suggested that regulation of immediate early genes egr-1
and c-fos by estrogen in MCF7 cells is mediated by their
serum response elements via non-genomic activation of the
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raf-MAPK signaling pathway

(Duan et a l . , 2001; Pratt et

al., 1998). The function of numerous transcription
factors including AP-1 and ERs themselves is regulated by
phosphorylation (Kato et al., 1995; Whitmarsh and Davis,
1996). Therefore, the modulation of kinase activities by
ERs is likely to contribute to fine-tuning of
transcriptional regulation depending on the combination
of transcription factors bound to a given promoter. In
this way, non-genomic and genomic actions of estrogen may
be intimately linked via cross-regulatory loops.
The complexity of action mechanisms of ERs suggests
that nature has engineered multiplicity into ER biology
to fulfill different functions in different cells.

1.2. ER-interacting proteins

The actions of ER result from the interplay of all
of factors that are involved. As described above, ERmediated transactivation is the process of the
intercommunication between ER and the transcription
machinery. Thus, the distinct characters of ligands and
different attributes of ER subtypes are eventually
integrated into the transcription machinery. Among the
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main players in this process are the cofactors because
they integrate differential signals and diversify the
regulation to amplify specificity of transcription. A
growing number of proteins have been identified in this
category through its direct interaction with ER as well
as other nuclear receptors in a ligand-dependent manner,

1.2.1. SRC/pl60 family
ER-associated protein (ERAP)140 and ERAP160
(subsequently cloned as SRC-1 which is the first member
of SRC/pl60 family, see below) were identified through
GST pull down assays as the first ER interacting proteins
(Halachmi et al., 1994). The potential role of ERAP160 in
ER functions was suggested by the observation that it
failed to interact with either antagonist-bound ER or
with transcriptionally defective mutants of ER (Halachmi
et al., 1994). SRC-1 was originally cloned through its
interaction with LBD of PR by yeast two-hybrid analysis
(Onate et al., 1995). The second member of this family
is identified as TIF2/GRIPl/NcoA-2/SRC-2 (Hong et al.,
1997; Voegel et al., 1996). Concomitantly,
AIBl/pCIP/ACTR/RAC3/TRAM-l/SRC-3 (Anzick et al., 1997;
Chen et al., 1997; Li et al., 1997; Takeshita et al.,
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1997; Torchia et al., 1997) was discovered as the third
member. These proteins share a conserved domain structure
including the most conserved N-terminal basic helix-loophelix (bHLH) and Per/Arnt/Sim (PAS) domains that are
implicated in protein-protein interactions (Aranda and
Pascual, 2001). At the C-terminal end of the proteins
reside two autonomous activation domains, a glutaminerich domain, and regions important for interaction with
CBP (Torchia et al., 1997) and for the weak intrinsic HAT
activity (Spencer et al., 1997). In the central part are
located receptor interacting domains (RIDs) containing
three LXXLL motifs that are essential for the
interactions with nuclear receptors (Heery et al., 1997).
These motifs have been implicated in determining the
specificity of the interaction with nuclear receptors
through differential requirement of each LXXLL motif in
the interaction with specific receptors (Mclnerney et
al., 1998). For instance, ERa preferentially interacted
with the second motif and only one motif was sufficient
to support stable interactions. The flanking sequences
also contributed to the specificity of interaction and
are important for SRC-1 function as well as interaction
with ERa (Mclnerney et al. , 1998).
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The functional significance of these proteins was
well established by their ability to function as bona
fide coactivators in vivo. For instance, SRC-1 showed a
broad range of specificity in its function as a
coactivator for several nuclear receptors as well as
other transcription factors such as AP-1 and NF-kB. The
important role of SRC-1 in ER functions was suggested by
its stimulatory effect on the transcriptional activity of
both ERa and ER(3 and this effect was inhibited by
antiestrogens (Onate et al., 1995; Tremblay et al.,
1997). Moreover, the capability to reverse the ERmediated squelching effect on PR transactivation
indicated that this protein is a limiting factor that is
commonly recruited by both ER and PR. SRC-1 is also
implicated in cooperative synergism between AF-1 and AF-2
functions in ER through mediating functional interaction
between AF-1 and AF-2 domains. Interestingly, TIF2 (a
SRC-2) can stimulate ligand-dependent transcriptional
activity only by ERa (Voegel et al., 1996) but not by ER(3
(Bramlett et al., 2001). However, GRIP1, another SRC-2,
was shown to function as a very strong coactivator for
ER|3 on the collagenase promoter (Webb et al., 1998). SRC3 also showed functional preference in that it
selectively enhanced the transcriptional activity of ERa
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over that of ER(3 although it can interact with both ERa
and ER(3 (Suen et al., 1998). These studies suggested that
the specificity of ER functions is partly-this may be
significant-dictated by the intrinsic functional features
of SRC. This is consistent with the view that cofactors
are major players in amplifying the specificity of ER
function (reviewed in McKenna et al). Generation of
knockout mice lacking SRCs has illuminated their
physiological functions. The SRC-1 knockout mice were
viable and fertile but exhibited growth reduction in
estrogen target tissues (Xu et al., 1998). This included
defects in uterine response to estradiol and mammary
gland development in pregnant mice (Xu et al., 1998).
Despite its broad functions as seen in cellular assays,
the SRC-1 knockout mice showed relatively restricted
defects. This, coupled with the observation of increase
in TIF2 mRNA expression in SRC-1 knockout mice, indicates
that certain compensatory mechanisms are involved in
cofactor functions (Xu et al., 1998). Disruption of the
SRC-3 gene in mice resulted in more dramatic phenotypes
exhibiting growth retardation, delayed puberty, decreased
reproductive function and blunted mammary gland
development (Xu et al., 2000). Together with the original
observation of the amplification of the SRC-3/AIB1 gene
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in breast cancer

(Anzick et al., 1 9 9 7 ) , the defects in

the mammary gland development suggested a significant
role of this cofactor in this tissue.

1.2.2. P300/CBP
P300 and CBP were originally isolated by their
respective interaction with E1A (Eckner et al., 1994) and
cAMP-regulated enhancer binding protein (CREB) (Kwok et
al., 1994). They are now viewed as cointegrator proteins
that function as common cofactors for diverse
transcription factors to collate multiple signals into an
integrated cellular response (Kamei et al., 1996). In
this way, these proteins are involved in many important
cellular processes including development, differentiation
and oncogenesis (Goodman and Smolik, 2000). The
involvement of p300/CBP in nuclear receptor functions has
been suggested by gene deletion experiments, nuclear
injection of blocking antibodies and transfection assays
(Chakravarti et al., 1996; Chen and Okayama, 1987;
Hanstein et al., 1996; Kamei et al., 1996; Kawasaki et
al., 1998; Yao et al., 1996; Yao et al., 1998). Although
direct interaction of p300/CBP with ERa through its RID
has been clearly demonstrated in vivo and in vitro
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(Hanstein et al., 1996), p300/CBP is now believed to be
recruited to ERa via SRC-1 in the cell (Hanstein et al.,
1996; Torchia et al., 1997; Yao et al., 1996). With its
potent intrinsic HAT activity (Ogryzko et al., 1996)
p300/CBP has been believed to play a central role in ER
dependent transcription by remodeling chromatin. This has
been clearly demonstrated by the study with the cell free
transcription assays using chromatin template (Kraus and
Kadonaga, 1998). Similar to SRC-1, p300/CBP has been also
shown to mediate synergism between AF-1 and AF-2
(Kobayashi et al., 2000) through its interaction with AF1 domain of ERa and by facilitating phosphorylationdependent recruitment of SRC-1 to AF-1 domain of
ER(3 (Tremblay and Giguere, 2001).

1.2.3. AF-1 interacting proteins
Recently, MMS19, the human homologue of the yeast
DNA repair enzyme has been found to interact with the AF1 of ERa (Wu et al., 2001). Although it is not clear what
the physiological relevance of this interaction is it
might facilitate recruitment of RAC3 to the N-terminus of
ERa through its interaction with PAS domain of SRC-3/RAC3
(Wu et al., 2001) .
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Surprisingly, an unusual RNA molecule called Steroid
receptor RNA activator (SRA) has recently been described
as an AF-1 specific cofactor for several steroid
receptors including ERs (Lanz et al., 1999). SRA was
found to be recruited to ERa via a subfamily of RNAbinding DEAD-box proteins called p68/p72 which were
identified as ERa AF-1 specific coactivators (Endoh et
al., 1999; Watanabe et al., 2001). These proteins
interact directly with AF-1 region of ERa but not of ER(3.
This interaction was facilitated by phosphorylation by
MAPK and led to potentiation of AF-1 activity of ERa
(Endoh et al., 1999; Watanabe et al. , 2001).

1.2.4. Other ER-interacting proteins
There are many other factors that have been shown to
interact with ERs and to stimulate ER dependent
transcription including GTFs such as TBP (Sadovsky et
al., 1995), TFIIB (Sabbah et al., 1998), and TFIIH (Chen
et al., 2000b). Importantly, TFIIH has been shown to
phosphorylate Ser-118 in a ligand-dependent manner
through its interaction with ERa(Chen et al., 2000b).
This study proposed the novel mechanism by which AF-1
activity can be regulated by ligand and AF-2 activity.
Along with several HATs other chromatin remodeling
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factors such as SWI2/SNF2

(Ichinose et al., 1997) and

BRG-1 (DiRenzo et al., 2000) have been implicated in ER
dependent transcription. These proteins interact directly
with LBD of ERa in a ligand-dependent manner (DiRenzo et
al., 2000; Ichinose et al., 1997). This interaction
absolutely required AF-2 domain (DiRenzo et al., 2000;
Ichinose et al., 1997). In particular, BRG-1 is required
for the function of SRC-1 and p300/CBP suggesting their
cooperativity for ER function (DiRenzo et al., 2000).
Another emerging group of proteins that are involved in
nuclear receptor function by chromatin remodeling is
histone methyl transferase (HMT) (Kraus and Wong, 2002).
Coactivator-associated arginine methyltransferase 1
(CARMl)(Chen et al., 2000a; Chen et al., 1999), protein
arginine methyltransferasel (PRMT1) (Koh et al., 2001)
and PRMT2 (Qi et al., 2002) have been shown to enhance ER
dependent transcription synergistically with SRC-l/pl60
through their direct interaction with the AD2 activation
domain of SRC-l/pl60 but not directly with ER indicating
their role as secondary factors. Another important factor
for ER function is cyclin Dl indicating the tight link
between ER function and the cell cycle. Cyclin Dl
(without its CDK partner) was found to stimulate ER
dependent transcription via direct interactions, which
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were independent of ligand by recruiting SRC-1

(Zwijsen

et al., 1998; Zwijsen et al., 1997). The physiological
relevance was further highlighted by the recent
demonstration that the interaction between ER and cyclin
Dl was modulated by levels of cAMP in mammary epithelial
cells (Lamb et al., 2000).
Other cofactors such as TR-binding protein (TRBP)
(Ko et al., 2000), transcription intermediary factor 1
(TIF1) (Thenot et al., 1997), Coactivator independent of
AF-2 function (CIA) (Sauve et al., 2001), E6-AP (Nawaz et
al., 1999) and PPARgamma-coactivator-1 (PGC-1)
(Tcherepanova et al., 2000) were found to enhance ER
dependent transcription through their interaction with
ERs. The physiological relevance of the interaction of
these proteins with ERs remains to be studied.

1.2.5. Corepressors
Silencing mediator of RAR and TR (SMRT) (Horlein et
al., 1995) and nuclear receptor corepressor (NcoR) (Chen
and Evans, 1995) interact with the hinge region of RAR
and TR in the absence of ligand and mediate basal
repression of their respective target genes by recruiting
many other factors such as histone deacetylases (HDACs)
and Sin3 to form a repression complex (Jepsen and
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Rosenfeld, 2 0 0 2 ) . This complex coordinates

deacetylation

of histones resulting in a condensation of chromatin and
subsequent repression in transcription (Jepsen and
Rosenfeld, 2002). Although the importance of these
corepressors in nonsteroid hormone receptor function has
been well known, their involvement in steroid receptor
function was not yet fully demonstrated. However, ER has
been found to interact with NcoR/SMRT and this
interaction inhibits transcriptional activation in the
presence of partial agonist such as TAM (Jackson et al.,
19 97; Smith et al., 1997). Furthermore, SRC-1 mediated
TAM agonism was overcome by coexpression of SMRT
indicating that these two proteins compete for access to
partial agonist-bound receptor (Jepsen et al., 2000).
This finding suggested that the expression level of these
coregulators could be a determinant of tissue-selective
agonism or antagonism of TAM (Jepsen et al., 2000).
Further evidence for the involvement of NcoR/SMRT in ER
function came from the discovery of SMRT/HDAC1 associated
repressor protein (SHARP) by yeast two-hybrid analysis
through the C-terminus of SMRT (Shi et al., 2001). This
potent corepressor can attenuate SRA-induced ER
transactivation by squelching SRA through the interaction
of its RNA binding motifs with SRA and forming a complex
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with several other corepressor proteins including HDACs
(Shi et al., 2001). Interestingly, its mRNA level is
induced in the breast cancer cell line MCF-7 upon
treatment with E2 suggesting possible participation of
SHARP in the feedback mechanism for the attenuation of
the hormonal response (Shi et al., 2001).
The effort to find a bona fide corepressor for ER
has resulted in the cloning of REA (repressor of ER
activity) (Delage-Mourroux et al., 2000). This protein
represses the activity of both ERa and ER(3 through
interaction with ERs in the presence of antagonists but
does not affect transcription by other nuclear receptors,
REA-dependent repression could overcome SRC-1 mediated
stimulation of ER through its LXXLL motif.

1.3. TRAP/Mediator

The necessity for precise control of specific gene
expression during complicated cellular processes creates
numerous regulatory layers on the transcription process.
This results in a great number of components that are
involved in transcription. However, these protein
components of the transcription machinery can be grouped
into four categories by their functions: (1) sequence-
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specific DNA-binding transcription factors

(Mitchell and

Tjian, 1989); (2) chromatin remodeling factors including
ATP-dependent remodeling factors and histone-modifying
factors (Narlikar et al., 2002); (3) GTFs that are
required for accurate transcription initiation from core
promoters (Roeder, 1996); and (4) cofactors (Roeder,
1998). Cofactors, used loosely, include chromatin
remodeling factors. However, in this section, cofactors
are more specifically defined as the factors that are not
essential for basal transcription but that are necessary
for the optimal induction or repression by sequencespecific transcription factors without having intrinsic
site-specific DNA binding activity and function beyond
chromatin remodeling steps. The ultimate goal of the
transcription activation can be represented as the
facilitation of preinitiation complex (PIC) formation on
the promoter (Keaveney and Struhl, 1998; Roeder, 1996).
However, the access to the promoter is blocked by
intrinsic structural features of chromatin. Therefore,
the primary actions of transcription activators are (1)
recruitment of a chromatin remodeling factors (Narlikar
et al., 2002) and (2) induction of quantitative and
qualitative changes of GTFs to promote PIC formation on
the promoter (Roeder, 1996). Although many of
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transcriptional activators can directly and physically
interact with chromatin remodeling factors (Narlikar et
al., 2002) and/or GTFs (Roeder, 1996), a large body of
evidence suggested the major contribution of cofactors in
effecting the communication among transcription
activators, chromatin remodeling factors and/or GTFs
through protein-protein interactions (Roeder, 1998) .

1.3.1. Discovery of Mediator
The concept of cofactors originally emerged from the
"squelching effect" in which one activator could inhibit
the stimulatory activity of a second activator in vivo
(Gill and Ptashne, 1988; Triezenberg et al., 1988a;
Triezenberg et al., 1988b). This notion was further
corroborated by the requirement of additional activities
from partially purified TFIID fractions to support
activator function apart from what was then thought to be
cloned TFIID, but is now known to be TATA-binding protein
(TBP), the TATA binding component of TFIID (Hoffman et
al., 1990; Pugh and Tjian, 1990). These observations
pointed to a TBP-associated factor (TAF)-associated
cofactor activity.
The existence and function of novel cofactor
activities, which are distinct from TAF-associated
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activity, termed "mediator" in yeast (Flanagan et al.,
1991) and "upstream factor stimulatory activity" in
metazoan system (Meisterernst et al., 1991) was first
indicated by biochemical assays. These studies provided
direct evidence that these activities are required to
compensate the incapability of reconstituted
transcription system with purified GTFs to achieve the
optimal activity of sequence-specific activator-induced
stimulation above the basal activity, which was seen in
more crude system (Flanagan et al., 1991; Meisterernst et
al., 1991). The attempts to further purify these
activities to homogeneity were eventually succeeded in
isolation of the multiprotein complexes that could indeed
support activated-transcription in reconstituted
transcription systems with purified GTFs (Kim et al.,
1994; Malik et al., 2000).
Prior to these biochemical studies, yeast and
metazoan Mediator (or Mediator-related) complexes were
identified through independent studies. Early genetic
analyses identified two groups of genes that are involved
in transcriptional regulation (reviewed in Carlson, 1997)
in vivo. The first includes suppressors of RNA polymerase
B (II) (Srbs), and the other includes Galll, Rgrl, Rox3
and Sin4 (reviewed in Carlson, 1997). The genetic screens
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for suppressors of truncation mutation in the carboxyl
terminal domain (CTD) of the largest subunit of pol II,
rpbl, first identified nine genes: srb2 (Nonet and Young,
1989), srb4-6 (Thompson et al., 1993), and srb7-ll
(Hengartner et al., 1995; Liao et al., 1995). As they
were originally identified the proteins involved in CTD
function in vivo, SRB2, SRB4, SRB5 and SRB6 proteins,
together with TBP, were found in a multisubunit complex
that was associated with RNA polymerase II and bound
specifically to recombinant CTD protein (Thompson et al.,
1993). Further characterization of this complex, termed
holoenzyme, revealed that this complex could stimulate
activated-transcription by GAL-VP16 (Koleske and Young,
1994) and contained all nine SRB proteins and GAL11,
together with TFIIB, TFIIF and TFIIH (Barberis et al.,
1995; Hengartner et al., 1995; Koleske and Young, 1994;
Koleske and Young, 1995; Liao et al., 1995).
The first human Mediator complex was discovered as
TRAP (thyroid receptor-associated proteins) complex
(Fondell et al., 1996). This complex was isolated through
its intracellular association of the ligand-bound thyroid
receptor (Fondell et al., 1996). TRAP complex was later
found to be equivalent, in composition, function, and
action mechanism (Ito et al., 1999), to SRB- and MED-
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containing Coactivator Complex (SMCC), which was isolated
through independent efforts to identify a human
holoenzyme complex corresponding to yeast holoenzyme (Gu
et al., 1999). Other biochemical studies reported other
human Mediator-related complexes including vitamin D
receptor-interacting proteins (DRIP) (Rachez et al.,
1998), negative regulator of activated transcription
(NAT) (Sun et al., 1998), activator-recruited complex
(ARC) (Naar et al., 1999) and coactivator required for
Spl (CRSP) (Ryu and Tjian, 1999).

1.3.2. Structure of Mediator
1.3.2.1. Subunit composition
Yeast Mediator is composed of about twenty one
subunits (Myers and Kornberg, 2 000; Boube et al., 2 002):
above-mentioned nine Srbs (Srb2-ll); other genetically
identified subunits including Gal11, Nutl, Rgrl, Rox3,
Sin4, Med3/Hrsl/Pgdl, Med9/Cse2 and Medl0/Nut2 (Carlson,
1997; Myers and Kornberg, 2000); and the last seven novel
proteins (Med 1,2,4,6,7,8, and 11) that were
biochemically identified by their presence in the
SRB/Mediator complex (Myers et al., 1998).
Metazoan Mediator complexes appeared to vary
significantly in size and composition (Malik and Roeder,
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2 0 0 0 ) . However, close comparison of their compositions
and sizes reveals that they are essentially derived from
an identical or a very similar cellular unit (Malik and
Roeder, 2000). The largest human Mediator complex,
TRAP/Mediator complex contains approximately twenty-five
subunits (Gu et al., 1999; Malik et al., 2000; Baek et
al., 2002). Among them, seventeen subunits are human
orthologs of yeast Mediator components; TRAP2 4 0/SRB9,
TRAP230/SRB8, TRAP220/MED1, TRAP170/RGR1, hSUR2/Galll,
TPA-inducible gene (TIG)1/PC-associated Q-rich
protein(PAQ)/ARC105/MED9, TRAP95/Sin4, TRAP80/SRB4,
CDK8/hSRB10, p36/MED4, hMED7, Cyclin C/hSRBll, hMED6,
TBP-related-factor-proximal protein (TRFP)/SRB2,
TRAP25/Medll, hSRB7, hSOHl, hNUT2/MED10 (Malik and
Roeder, 2000; Boube et al., 2002) and TRAP100, p37 are
considered as species specific components. Additional
subunits, p97, p93, p78, p22, pl2 remain to be
characterized (Malik and Roeder, 2000). Any variation in
composition and size of the metazoan Mediator complexes
may be possibly in part due to different isolation
procedures (Malik and Roeder, 2000). In addition, the
intrinsic modular properties and/or different cellular
states of the Mediator complexes might also lead to
variable association of the components (Malik and Roeder,
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2000; Myers and Kornberg, 2 0 0 0 ) , as reported in yeast
Mediator (Kang et al., 2001). On the basis of
compositional complexity and sizes, these various
complexes can be classified into the smaller complexes
including PC2, CRSP and the murine Mediator and the
larger complexes including TRAP/Mediator, ARC, DRIP and
NAT complexes (Malik and Roeder, 2000). In view of the
notion that Mediator is a dynamic and modular
organization, the smaller complexes could be considered
as subcomplexes of the larger complexes as represented by
PC2 and TRAP/Mediator (Malik et al., 2000) as well as
CRSP and ARC-L (Naar et al., 1999; Ryu and Tjian, 1999).

1.3.2.2. Three-dimensional structure
As inferred from the comparison of their subunit
composition, the recent studies by electron microscopy
(EM) revealed considerable similarities between
TRAP/Mediator and ARC-L as well as between CRSP and
murine Mediator complex (Dotson et al., 2000; Taatjes et
al., 2002). Additionally, comparison of murine Mediator
and human TRAP complex hinted that structure of murine
Mediator appeared to be a substructure of TRAP/Mediator
(Dotson et al., 2000). Consistently, superposition of the
structures of CRSP and ARC-L demonstrated that CRSP is
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essentially a substructure of ARC-L

(Taatjes et al.,

2002). More importantly, these structural analyses
revealed significant structural features of Mediators. In
the holoenzyme (Mediator and RNA polymerase II) state,
three domains termed head, middle and tail of Mediator
were extended and wrapped around a globular polymerase,
in contrast to the more compact structure of its isolated
state, suggesting that Mediator undergoes conformational
changes in order to complex with polymerase (Asturias et
al., 1999). Subsequent EM studies of CRSP complex showed
activator-specific conformations of CRSP as distinct from
its structure of the isolated form. Interestingly,
certain activator i.e. VP16 can induce the conformation
similar to CTD bound form (Naar et al., 2002; Taatjes et
al., 2002). It was suggested that activator (VP16) could
substitute for, but not compete with, a potential
function of the CTD in activating transcription by
inducing a CTD-bound conformation in the CRSP- In this
way, activator can overcome CTD-dependent regulatory
mechanisms that would otherwise moderate transcription
initiation. Another possibility could be that activator
binding induce such structural change in the conformation
of Mediator to facilitate the formation of a holoenzyme
complex which help basal machinery including RNA
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polymerase II to form preinitiation complex at the
promoter.

1.3.3. Function of Mediator
Mediator is now considered as a sensor, integrator,
and processor (Kang et al., 2001). In this view, Mediator
fulfills its primary function, as originally conjectured,
by interconnecting diverse gene-specific regulatory
proteins to the basal transcription machinery and
providing more regulatory surfaces to transcription
apparatus with its modular and dynamic organization.
Three lines of evidence support this view. First of
all, Mediator facilitates activated-transcription through
direct interaction with a number of transcription
activators including VP16 (Hengartner et al., 1995), Spl
(Ryu and Tjian, 1999), adenovirus oncoprotein E1A (Boyer
et al., 1999), and various nuclear receptors such as
thyroid receptor (Fondell et al., 1996), vitamin D
receptor (Rachez et al., 1998), estrogen receptor (ER)
(Kang et al., 2002), peroxisome proliferator-activated
receptor y2 (PPARy 2) (Ge et al., 2002) and hepatocyte
nuclear factor 4 (HNF-4) (Malik et al., 2002). Secondly,
the roles for Mediator in basal transcription have been
supported by the following observations: (1)

50

copurification of yeast Mediator with polymerase II
(Thompson et al., 1993; Kim et al., 1994; Koleske and
Young, 1994), (2) association of TBP with SRB proteins
(Koleseke et al., 1992; Thompson et al., 1993) (3) the
requirement of Srb2 and Srb5 for stable PIC formation
(Koleseke et al., 1992; Thompson et al., 1993), (4)
complete shut-off of transcription from essentially the
entire genome by the mutation in srb4, one of the core
subunits of yeast Mediator (Holstege et al., 1998) and
(5) TRAP/Mediator affected the basal transcription in
TRAP/Mediator-depleted nuclear extract as well as
activator-dependent transcription activity (Baek et al.,
2002; Mittler et al., 2001). Finally, a number of genetic
and biochemical analyses have suggested that yeast
Mediator is constituted with three functional modules
termed the Galll, Med9/10, and Srb4 modules (Carlson,
1997; Lee and Kim, 1998; Lee et al., 1999; Han et al.,
1999; Han et al., 2001; Kang et al., 2001; Boube et al.,
2002). This is consistent with the three-dimensional
structure reconstructed by EM study, which also suggested
dynamic properties of Mediator (Asturias et al., 1999;
Dotson et al., 2000). The Galll module, constituting the
tail region, (Dotson et al., 2000), includes Galll, Rgrl,
Sin4, Med2, and Med3 (Lee and Kim, 1998; Lee et al.,
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1999). As Galll, Rgrl and Sin4 are originally

identified

by genetic analyses for transcriptional regulators
(reviewed in Carlson, 1997), this module is thus proposed
to function mainly in receiving signals from genespecific regulators (Lee et al., 1999; Han et al., 1999).
In support of this idea, the proteins in this module were
shown to be required for transcriptional activation and
repression through direct interaction with activators and
repressors (e.g., Gal4, Gcn4, Swi5, and Tupl) via
distinct and/or common binding surfaces (Bhoite et al.,
2001; Han et al., 2001; Park et al., 2000, Han et al.,
1999; Lee et al., 1999; Myers et al., 1999). The middle
domain of Mediator is the Med9/10 module together with
the N-terminal portion of Rgrl (Dotson et al., 2000).
This module is proposed to play a role in relaying
regulatory signals (Han et al., 2001; Kang et al., 2001)
through physical interactions among the Mediator subunits
and basal transcription machinery (Kang et al., 2001).
This module is composed of two stable substructures: the
Med9 submodule containing Medl, -4, and —9, as indicated
in genetic analyses, is thought to be involved in
repression through physical interaction with Srbl0/ll,
whereas the MedlO submodule comprising Srb7, Med7, MedlO,
and possibly Nutl may transfer activating signals to the
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basal transcription machinery

(Han et a l . , 2001; Kang et

al., 2001). The head domain, Srb4 module, includes Srb2,
-4, -5, -6, Rox3, Med6, -8, and -11 (Kang et al., 2001).
This module is thought to function as a signal processor
that directly modulates activity of polymerase II through
the physical interaction with polymerase II. This idea
has emerged from the following observations: (1) the
reconstituted SRB4 module interacts with basal
transcription machinery and enhances basal transcription
in a cell-free assay without major effect on activated
transcription and CTD phosphorylation (Kang et al.,
2001); (2) srb2, -4, -5, and -6 genes were originally
identified as suppressors of CTD truncation (Nonet and
Young, 1989; Thompson et al., 1993); and (3) the apparent
physical contacts between the head domain and Pol II was
shown by EM studies (Asturias et al., 1999). Mediator
under certain condition contains an accessory SrblO
module composed of four Srbs, Srb8—11 (reviewed in
Carlson, 1997) whose physical location within Mediator is
yet unknown. This module is implicated in transcriptional
repression via a modification of the polymerase II CTD
prior to initiation (Hengartner et al., 1998) and through
interactions with the Med9 submodule at least by a
physical interaction of the SrblO with Medl and Med4
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(Kang et al., 2 0 0 1 ) . Consistently, the depletion of the
SrblO and Srbll pair by nutrient deprivation was
associated with upregulation of a specific gene subset
(Holstege et al., 1998). Moreover, the negative cofactor
activity of TRAP/Mediator (Gu et al. 1999) was attributed
to the enrichment of CDK8/SRB10 due to isolation
procedures. This is because phosphorylation of cyclin H
subunit of TFIIH by CDK8/SRB10 represses both the ability
of TFIIH to activate transcription and its CTD kinase
activity (Akoulitchev et al. , 2000).
Regarding metazoan Mediator complex, its modular
properties are not yet as clearly elucidated as yeast
Mediator. However, emerging evidence indicated the
modular properties of metazoan TRAP/Mediator. For
example, as mentioned above, PC2 was found to be a
submodule of TRAP/Mediator (Malik et al., 2000) and most
subunits of CRSP are included in ARC complex (Naar et
al., 1999). Moreover, the purified Mediator complex
isolated from murine cells lacking Sur2 contains reduced
amount of murine TRAP95 and murine TRAP100 (Stevens et
al., 2002). Consistently, the TRAPlOO-deficient
TRAP/Mediator complex derived from mouse embryonic
fibroblasts of TRAP100 knockout mice also lacks TRAP95
and SUR2, with a reduced amount of CDK8/hSRB10,
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suggesting that these subunits may form a submodule
et al., 2002).
Another line of evidence suggesting the modular
properties of metazoan Mediator is that each subunit (or
group of subunits) of Mediator serves as a specific
target for a distinct group of transcription factors. For
example, TRAP220 is shown to be a main anchor for various
nuclear receptors whereas TRAP80 serves as a specific
target for p53 and VP16 (Ito et al., 1999). Human Sur2 is
implicated as an integrator of the E1A and RAS signaling
pathways (Boyer et al., 1999), while TRAP230 is involved
in Wnt signaling (Zhang and Emmons, 2000). These studies
also reinforce the idea that TRAP/Mediator, as a common
and general cofactor, integrates multiple signals from
diverse transcriptional activators to coordinate afferent
signals from various signaling pathways.

1.3.3.1. Functional mechanism of Mediator:
The relationship with chromatin remodeling factors
Transcriptional activation may be viewed as a twostep process, an antirepression process to relieve the
repression imposed by high order chromatin structure
followed by PIC formation at the promoter (Roeder, 1998).
The observation that TRAP/Mediator does not contain
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(Ito

intrinsic HAT activity and functions on naked DNA
template in a purified system indicates that
TRAP/Mediator mainly contributes to the PIC formation
step (Roeder, 1998; Malik and Roeder, 2000).
Additionally, the report of the competitive interaction
of TRAP220 and TIF2 with TR or PPARy (Treuter et al. ,
1999) has suggested mutually exclusive recruitment of
these proteins to transcription activators. Another
important finding was the sequential interaction of
cofactors with ligand-bound TR, TR-pl60/SRC-CBP/pCAF
followed by TR-TRAP (Sharma et al., 2000). These have
proposed the sequential multi-step model for
transcription activation (Roeder, 1998; Ito and Roeder,
2001 and references therein). In this model,
transcription activation occurs in four steps: (1)
activator binding to target sites within chromatin; (2)
recruitment of chromatin remodeling factors including
ATP-dependent nucleosome remodeling factors and HATs; (3)
exchange of chromatin remodeling factors with
TRAP/Mediator; (4) recruitment of RNA polymerase II and
GTFs to form PIC.
A recent report provided evidence for this model
showing that TR, upon ligand binding, recruited HATs such
as SRC-1, GRIP-1 and p300 ahead of the TRAP220 (Sharma
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and Fondell, 2 0 0 2 ) . Prior to this study, however, the
contrasting observation that TRAP220/PBP and AIB1
concurrently occupied the cathepsin D promoter upon
estrogen treatment had proposed the simultaneous and
combinatorial recruitment model (Shang et al., 2000). The
discrepancy between these studies might be attributed to
the intrinsic differences between ER and TR (Sharma and
Fondell, 2002). However, and more importantly, the
observation of the requirement of pl60/GRIPl for
TRAP220/PBP recruitment (Shang et al., 2000), actually
provided evidence for the sequential action of these
cofactors. Interestingly, Burakov et al suggested that
TRAP220 subunit may have been recruited to the pS2
promoter earlier than the rest of TRAP/Mediator complex
(Burakov et al., 2002). Taken together, these results
indicated that SRC/pl60 and TRAP220/PBP appeared to be
recruited to the promoter simultaneously but the concrete
recruitment of TRAP/Mediator complex might occur at the
later step.

1.3.3.2. Physiological roles of Mediator subunit
In the multicellular organism, it is necessary to
accommodate and incorporate diverse regulatory
information needed to coordinate and specify the various
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cell types. To fulfill this necessity, TRAP/Mediator, as
a multiprotein complex, may provide a physical interface
whereby subunits serve as specific targets for distinct
regulatory signals. The genetic analyses in model
eukaryotes have provided insights of the involvement of
Mediator in the cellular mechanisms that allow the tight
transcriptional regulation necessary for successful
differentiation and/or development.
Three genes encoding metazoan counterpart of MED6,
SRB4, and SRB7 are essential for cell viability
suggesting their general function in RNA polymerase II
transcription (Tudor et al., 1999; Boube et al., 2000;
Gim et al., 2001). In contrast to this, some of metazoan
mediator subunits play more restricted but crucial roles
in transcriptional regulation. For example, disruption of
the murine TRAP100 has revealed that TRAP100 is not
essential for cell viability per se, however, null mutant
mice die at an early developmental stage with severe
malformations (Ito et al., 2002). Similarly, although
metazoan counterparts of Galll/Sur2, MED1/TRAP220,
SRB8/TRAP230, and SRB9/TRAP240 are not required for cell
viability or proliferation per se, these genes are
necessary for the viability of the whole organism
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(Stevens et a l . , 2002; Treisman, 2001; Boube et al.,
2000; Ito et al., 2000; Zhu et al., 2000).
These subunits play their specific roles in
transcriptional response to various signaling pathways,
which are involved in cell differentiation through
environment-directed cell fate decisions. The C. elegans
Sur2/Galll, which functions downstream of the Surl MAP
kinase (MAPK) pathway, is involved in a Ras-mediated
signal transduction pathway (sur, suppressor of ras),
which plays roles in the process of vulval induction
(Singh and Han, 1995). Its null mutant showed pleiotropic
phenotypes including partial larval lethality and sterile
adults (Singh and Han, 1995). Consistently, human Sur2
functionally interacts with MAPK-modified form of Elkl
(Boyer et al., 1999). Furthermore, disruption of murine
sur2 in embryonic stem cells leads to defective gene
activation specifically by Elkl, but not by many other
transcription factors (Stevens et al., 2002). These
studies pointed to the conserved function of metazoan
Galll, involving transcriptional regulation,
particularly, in response to MAPK-dependent cell
signaling.
Srb8 and Srb9 represent another example of
conservation of their specific roles in cell
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differentiation in response to cell signaling pathways.
In the slime mold, the protozoan counterpart of Srb9,
namely AmiB, is specifically required to modify gene
expression in response to nutrient depletion through its
function in a cAMP-dependent signaling pathway (Kon et
al., 2000). SRB8/TRAP230 and MED1/TRAP220 proteins in C.
elegans were implicated to act in concert within a
Mediator-related complex to block improper activity of
the Wnt signaling pathway in V6 neuroblasts (Zhang and
Emmons, 2001) and thus function in specification of V6
cells via the pal-1-dependent genetic cascade as their
genes, srb8/sopl and medl/sop3 were originally isolated
as sop, suppressor of pal-1 (Zhang and Emmons, 2000,
2001). In Drosophila, dSrb9/TRAP240 gene was originally
identified as dose-sensitive modifiers of cell identity
functions of the homeotic gene Sex combs reduced (Boube
et al., 2000). Subsequent studies suggested that
dSrb9/TRAP240 and dSrb8/TRAP230 function cooperatively to
mediate developmental signals in early eye
differentiation (Treisman, 2001).
Another way to coordinate cellular functions is
mediated via hormone signaling pathways. The TRAP220 is
thought to be the pivotal subunit to mediate hormone
action based on the observations of its ligand-dependent
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interactions with various nuclear receptors

(Yuan et al.,

1998), defective TR function in TRAP220-/- mice (Ito et
al., 2000) and its essential functions in PPARystimulated adipogenesis but not for MyoD-stimulated
myogenesis (Ge et al., 2002). These studies provide
strong evidence for the roles of TRAP220 in specific
cellular processes. Altogether, the above-mentioned
studies strongly supported the involvement of the
Mediator complex in many important decisions controlling
cell differentiation and development.

1.3.4. Conservation throughout evolution
The earlier observation that metazoan activators
also can function in yeast hinted a high degree of
functional conservation of the transcription apparatus
over eukaryotic evolution (Flanagan et al., 1991). Recent
studies supported not only functional (see above) but
also structural conservation of Mediator. Electron
microscopy data revealed the striking similarities in the
overall appearance of isolated yeast and metazoan
Mediator complexes (Asturias et al., 1999; Dotson et al.,
2000). In addition, all the known human Mediator subunits
shared counterparts in fruit flies and worms indicating a
high degree of structural conservation among metazoan
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Mediator complexes

(Kwon et al., 1999) (Park et al.,

2001) (Boube et al., 2000). Moreover, the extensive
analyses of the newly available genomic sequences from
eukaryotic species led to the identification of 12
additional Mediator subunits conserved from yeast to
human: Srb2/Trfp, Srb5/Med28b, Srb6/Surf5, Srb8/TRAP230,
Srb9/TRAP240, Galll/Sur2, Sin4/TRAP95, Medl/TRAP220,
Med4/TRAP36, Med8/ARC32, Med9/ARC105, and Medll/TRAP25
(Boube et al., 2002). The conservation of overall subunit
composition in Mediator from yeast to human suggests that
the functional organization of yeast Mediator might be
highly conserved in metazoan complexes (Boube et al.,
2002). Interestingly, a few mediator proteins are
apparently present only in yeast and/or filamentous
fungi, i.e., Nutl, Rox3, Med2, and —3 (Myers and
Kornberg, 2000). Conversely, some human Mediator
components appear specific to metazoans and/or plants,
i.e., TRAP37, TRAP100, CRSP70, ARC42, and ARC92 (Boube et
al., 2002). This, together with variations in the primary
sequences of individual subunits might have been
diversified during evolution to accommodate the speciesspecific regulatory inputs emerging from novel genespecific transcription factors in eukaryotic evolution
(Boube et al., 2002) .
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Chapter

2

Materials and Methods
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A number of experimental procedures and materials
have been repeatedly used throughout this work. They are
usually described just once in the chapter where they
were first used without being repeated in subsequent
sections, unless significant modifications occurred.

2.1. Materials and Methods for Chapter 3.

Commercial reagents.
17(3-estradiol (cat# E-2257) and N-lauroyl sarkosyne
(Sarkosyl,cat# L-5777) were purchased from Sigma. Fetal
bovine serum (cat# 16000044)was purchased from Gibco and
Calf serum (cat# 12133-500M) was from JRH.

Buffer BCn.
20 mM Tris-HCl pH7.9 at 4°C, 20% (vol/vol) glycerol, 0.2
mM EDTA, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM
Dithiothreitol (DTT), supplemented with n mM of KCI.

Plasmids.
Plasmids encoding glutathione S-transferase (GST)-ERpLBD
(243-530) were created by inserting the corresponding
PCR-generated human ER(3 (hER(3) derivatives into the pGEX

64

vector

(Pharmacia). hER(3 cDNA (a generous gift by Dr.

Muramatsu) was used as templates for PCR reaction.
GST-ERaLBD (302-595) was generously provided by Mitsuhiro
Ito.

Cell Lines.
Immortalized mouse embryo fibroblasts (MEFs) from wild
type and TRAP22 0_/" mice (Ito et al., 2000) by
transformation with SV40 large T antigen were provided by
Chao-Xing Yuan. HeLa derived cell line that stably
expresses FLAG(f)-tagged Nut2 proteins (f:Nut2) (Malik et
al., 2000) was used to purify TRAP/Mediator complex.

Cell Culture.
MEFs were maintained in Dulbeco's Modified Eagle's medium
(DMEM) with 10% fetal bovine serum. HeLa cells were
maintained in Joklik minimal essential medium with 10%
calf serum and then transferred to DME-P04 medium
containing 10% calf serum to achieve high density
(107ml) .

Extract Preparation.
Nuclear extracts and S100 extracts were prepared as
described previously (Dignam et al., 1983).
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Immunoaffinity purification of FLAG-tagged proteinassoiciated complex.
Typically, one milliliter of nuclear extract prepared
from the cell line was adjusted to 300 mM KCI with 0.05%
(vol/vol) Nonidet P-40 (NP-40) and incubated with 2 0|xl of
anti FLAG M2-agarose beads (Sigma), which had been
preequilibrated with BC300-0.05% (vol/vol) NP40, at 4°C
for 4-6 hours with gentle rotation. After 5 times of
washing with BC300-0.1% (vol/vol) NP-40, the proteins
were eluted by incubation of 20[xl of BC300-0.05%
(vol/vol) NP-40 with 0.2 mg/ml of the FLAG peptides at
4°C for 3 0 minutes.

Bacterial Expression of GST fusion proteins.
GST and GST fusion proteins were expressed and purified
as described previously (Burakov et al., 2000).

GST-Pull-Down Assays with Nuclear Extracts.
GST pull-down assays were performed as described
previously (Rachez et al., 1998). Before incubation with
HeLa nuclear extract, all glutathione-Sepharose beadimmobilized GST or GST-fusion proteins were normalized to
equimolarity following quantitation by SDS-PAGE.
Immobilized GST or GST-fusion proteins (20 u.g) were
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preincubated for 1 hour at 4°C with ligand

(1 uM E2)or

carrier in binding buffer (20 mM N-2hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES)KOH, pH 7.9, 20% (vol/vol) glycerol, 0.2 mM EDTA, 180 mM
KCI, 1 mM DTT, 0.05% (vol/vol) NP-40, 0.5 mM PMSF)
containing lmg/ml BSA. Immobilized proteins on beads were
then incubated at 4°C for 6-14 hours with 4-10 mg of HeLa
nuclear extracts adjusted to 180 mM KCI, plus 1 .uM E2 or
carrier (ethanol). After 5 times of washing with 1 ml of
washing buffer (20 mM HEPES-KOH, pH 7.9, 20% (vol/vol)
glycerol, 0.2 mM EDTA, 180 mM KCI, 1 mM DTT, 0.1%
(vol/vol) NP-40, 0.5 mM PMSF), bound proteins were eluted
by incubating the beads with washing buffer containing
0.2% (vol/vol) sarkosyl. The eluates were subjected to 420% gradient SDS-PAGE, and then analyzed either by silver
staining with Rapid Ag Stain Kit (ICN) or by western blot
with ECL (Amersham) according to manufacturer's
instructions.

Preparation of proteins for Mass Spectral Analysis.
For mass spectral analysis, eluates from GST-pull down
with were subject to SDS-PAGE followed by Zinc staining
(BioRad) according to manufacturer's instruction. The
polypeptides were extracted from the gel and analyzed by
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MS/MS by Dr. Wenzhu Zhang at Brian Chait's Lab. The MS/MS
data were analyzed by Masscot.

2.2. Materials and Methods for Chapter 4.

Plasmids.
GST-ERaAB (1-180) and GST-ER(3AB (1-153) were created by
inserting the corresponding PCR-generated human ER(hER)
derivatives into the pGEX vector (Pharmacia). hERa cDNA
(purchased from ATCC) was used as template for PCR
reaction. The plasmids for ER baculoviral expression were
created by subcloning FLAG-tagged hERa(full-length
cDNA) and hER(3( full-length cDNA) into pVL1392 vector
(Invitrogen).
4EREA53 was generously provided by Dr. Chengming Chiang
(Wu et al., 1999) .

Baculoviral Expression of Recombinant ER proteins.
Recombinant FLAG-tagged ERs were expressed as described
previously (Wu et al., 1999) with slight modifications.
Briefly, 1 pg of each plasmid was incubated with 0.25 pg
of Bac3000 linear DNA (Novagen), 1 jul of cationic
liposome solution (Novagen), and 0.5 ml of Grace's
medium. The mixture was vortexed vigorously, left at room
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temperature for 15 min, and then added to a 60-mm plate
containing ~2 x IO6 Sf9 cells. After incubation for 4
hours, 1.5 ml of TNM-FH was added to the plate.
Incubation was continued in a 2 7 °C humidified chamber
for 5 days. The supernatant, collected after pelleting
cells at 3,000 rpm for 5 min, was designated as the PO
virus stock. 0.5 ml of PO was incubated with -4xl05 Sf9
cells in a 60-mm plate containing 3 ml of TNM-FH. After 5
days, the supernatant (PI virus, 0.5 ml) was used to
infect 6xl06 Sf9 cells in a 150-mm plate containing 25 ml
of TNM-FH. The supernatant (P2 virus, 5 ml), collected
after 5 days of incubation, was used to infect 250 ml
(~0.6xl06 cells/ml) of Sf9 cells in suspension. Fifty ml
of the final P3 virus stock, collected after a 5-day
incubation, was then used to infect 500 ml (1 xlO6
cells/ml) of Sf9 cells for protein production, which was
conducted for 48 to 60 hours. In the interim, estradiol,
if included, was added to the medium at a final
concentration of 10 nM, 16 h before harvest.

Purification of Recombinant ER proteins.
To purify FLAG-tagged ER, cells were collected by
centrifugation at 3000 rpm for 10 minutes in a JS 4.2
rotor at 4 °C. After washing with cold phosphate-buffered
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saline (PBS) nuclear extract was prepared as described
previously (Dignam et al., 1983) with modifications.
Instead of adding low salt buffer and high salt buffer
separately, nuclear extract buffer (20 mM Hepes, pH 7.9,
25% (vol/vol) glycerol, 0.2 mM EDTA, 420 mM NaCl, 1 mM
DTT, 0.05% (vol/vol) NP-40, 0.5 mM PMSF, ImM Benzamide,
ImM Na3V04, 1\M E2) was used to extract nuclear proteins.
14 ml of the nuclear extract was incubated with 0.1 ml of
anti-FLAG M2-agarose (Sigma) at 4 °C for 4 to 6 hours.
The immobilized proteins were then washed 5 times with 10
ml of BC600-0.1% (vol/vol) NP-40 followed by washing with
BC100-0.05% (vol/vol) NP-40 and finally eluted with
elution buffer (BC100 for the first elution, and BC300
for the next elution) containing 0.2 mg/ml FLAG peptide
and 0.05% (vol/vol) NP-40.

Cell lines.
HeLa-derived cell lines expressing FLAG(f)-tagged Thyroid
hormone receptor (f:TR) (Fondell et al., 1996),
f:CDK8/SRBlO (Gu et al., 1999), f:TRAP220AB(1-670)
(C.X.Y. and R.G.R, unpublished) were used to purify the
corresponding TRAP/Mediator complexes containing these
FLAG-tagged proteins. Chao-Xing Yuan established a HeLaderived cell line (C8) that stably expresses f:hERaAAB
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(160-595), which was used to purify the
hERaAAB-associated proteins.

Antibodies and Western Blot Analysis.
Antibodies against TRAP/Mediator subunits were described
previously (Yuan et al., 1998) (Ito et al., 1999) (Malik
et al., 2000). Western blot analyses involved standard
procedures with an enhanced chemiluminescence detection
kit (Amersham) according to manufacturer's instruction.

GST-pull down assays with purified proteins.
GST pull-down assays were performed as described in the
previous section. Instead of nuclear extracts the
purified complex supplemented with 2 mg/ml of BSA was
incubated with immobilized proteins on beads at 4°C for
6-14 hours under the same binding condition then
processed and analyzed as described previously.

Immunoaffinity pull down assays.
All anti FLAG M2-agarose bead-immobilized f:ER proteins
were normalized to equimolarity following quantitation by
SDS-PAGE. Immobilized f:ER proteins (10 .ug) on beads as
well as the same volume of empty M2-agarose beads were
preincubated for 1 hour at 4°C with ligand (1 uM E2)or
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carrier in binding buffer

(20 mM HEPES-KOH, pH 7.9, 20%

(vol/vol) glycerol, 0.2 mM EDTA, 180 mM KCI, 1 mM DTT,
0.05% (vol/vol) NP-40, 0.5 mM PMSF) containing lmg/ml
BSA. The beads were then incubated at 4°C for 6-14 hours
with 8-10 mg of HeLa nuclear extracts adjusted to 180 mM
KCI, plus 1 .uM E2 or carrier. After 5 washes with 1 ml of
washing buffer (20 mM HEPES-KOH, pH 7.9, 20% (vol/vol)
glycerol, 0.2 mM EDTA, 180 mM KCI, 1 mM DTT, 0.1%
(vol/vol) NP-40, 0.5 mM PMSF) bound proteins were eluted
by incubating the beads with washing buffer containing
0.2 mg/ml of FLAG peptides. The eluates were subjected to
4-20% gradient SDS-PAGE, and then analyzed by western
blot with ECL (Amersham) according to manufacturer's
instructions.

In vitro translation of ER.
35S-labelled ER(3 was expressed by TNT T7 coupled
reticulocyte lysate systems (Promega cat#L4610) according
to manufacturer's instructions.

Interactions of purified TRAP/Mediator and full-length
ER.
TRAP/Mediator complex purified from the cell line
expressing f:TRAP220AB was immobilized on anti FLAG M2-
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agarose beads. Translation mixture containing the
expressed full-length ER and mock translation mixture
were preincubated for 1 hour at 4°C with ligand (1 u.M
E2)or carrier in binding buffer (20 mM HEPES-KOH, pH 7.9,
20% (vol/vol) glycerol, 0.2 mM EDTA, 180 mM KCI, 1 mM
DTT, 0.05% (vol/vol) NP-40, 0.5 mM PMSF). Immobilized
TRAP/Mediator on beads as well as the same volume of
control empty M2-agarose beads were then incubated with
each translation mixture at 4°C for 6-14 hours in the
binding buffer with 1 mg/ml of BSA plus 1 ,uM E2 or
carrier. After washing 5 times with 1 ml of washing
buffer (20 mM HEPES-KOH, pH 7.9, 20% (vol/vol) glycerol,
0.2 mM EDTA, 180 mM KCI, 1 mM DTT, 0.1% (vol/vol) NP-40,
0.5 mM PMSF) bound proteins were eluted by incubating the
beads with washing buffer containing 0.2 mg/ml of FLAG
peptides. The eluates were subjected to 4-20% gradient
SDS-PAGE, and then analyzed by western blot with ECL
(Amersham) according to manufacturer's instructions.

In Vitro Transcription Assays.
In vitro transcription assays were done by Mohamed
Guermah. Reactions contained TFIID, TFIIB, TFIIE, TFIIF,
TFIIH, RNA polymerase II, PC4 and other components
(TRAP/Mediator and ERs) as indicated. All factors were
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either recombinant or natural affinity-purified
components that were isolated and utilized under
previously described conditions (Guermah et al., 2001).

2.3. Materials and Methods for Chapter 5.

Plasmids
F:GAL4-ER LBDs were created by exchanging p53 of f:GAL4p53 (Thut et al., 1995) with ER LBDs of GST-ER LBDs
followed by subcloning into FASTBAC vector (Gibco). G5A53
described previously (Kundu et al., 2000) was kindly
provided by Woojin An. In transient transfection assays
the reporter construct was 3ERE-Xp-Luciferase construct
provide by Chao-Xing Yuan contained 3 ERE sites and
adenovirus major late core promoter in pGL2 vector
(Promega). pHEGO-Hyg (ATCC ) and pCXN2-ER(3 from Dr.
Muramatsu were used for mammalian expression of ERa and
ER(3 respectively. All TRAP220 constructs were generously
provided by Chao-Xing Yuan.

Cell lines.
HeLa-derived cell lines expressing FLAG(f)-tagged
TRAP220AB (1-670),f:TRAP220a,f:TRAP220b.f:TRAP220ab
(C.X.Y. and R.G.R, unpublished) were used to purify the
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corresponding TRAP/Mediator complexes containing these
FLAG-tagged proteins. TRAP220AB contains N-terminal part
of wild type TRAP220 (1-670). TRAP220a is the same Nterminal fragment with point mutation (LXXLL-LXXAA) in
the first LXXLL motif, TRAP220b is the one with point
mutation (LXXLL-LXXAA) in the second LXXLL motif and
TRAP22 0ab is the one with double mutation in both LXXLL
motives.

TRAP/Mediator-depleted Nuclear Extracts.
TRAP/Mediator-depleted nuclear extracts were provided by
Hwa Jin Baek and Xiaoting Zhang. Hwa Jin Baek used
antibody against 25-1 for immunodepletion of
TRAP/Mediator from HeLa nuclear extract as described
previously (Baek et al., 2002) and Xiaoting Zhang used
antibody against TRAP220 (Xiaoting Zhang and RGR,
unpublished results) for depletion of TRAP/Mediator from
Namalwa nuclear extract.

Transient transfection assays.
Transfection was carried out using FuGENE 6 reagent
(Roche) according to manufacturer's instructions with
slight modification. MEF cells were plated in 24-well
plates (5xl04 cells/well) in phenol red-free DMEM with
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10% charcoal-stripped fetal calf serum. The following day
transfection was carried out using FuGENE 6 reagent
(Roche) with 0.35 yiq of DNA comprising 1-5 ng of estrogen
receptor expression vector, 250 ng of luciferase reporter
vector, and 100 ng of TRAP220 or empty vector and pRL-CMV
for internal control. After incubation at 37 °C for 5
hours cells were treated with either E2 or carrier. After
another 36 hours cells were harvested and assayed for
luciferase activity by Dual Luciferase Assay system
(Promega) according to manufacturer's instruction.

Baculoviral Expression of GAL4-ER LBDs.
GAL4-ER LBDs were expressed and purified as described in
the materials and methods for chapter 4.

Purification of General Transcription Factors.
TFIIB (Ge et al., 1996), TFIIE (Ohkuma et al., 1995),
TFIIF (Wang et al., 1994) and PC4 (Ge et al., 1996) were
expressed and purified as described previously . TFIID
was purified from the cell line expressing f:TBP (3-10)
(Chiang et al., 1993) as described previously (Ge et al.,
1996). TFIIH and RNA polymerase II were immunoaffinity
purified from the cell lines expressing f:ERCC3 (C3a) and
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f:RPB9(B9b) respectively

(unpublished materials by Chao-

Xing Yuan).

In Vitro Transcription Assays with nuclear extract.
In vitro transcription assays with nuclear extracts were
carried out essentially as described previously (Dignam
et al., 1983). Transcription reactions were performed in
a final volume of 25 u.1. Transcription reaction contained
the indicated factors (such as GAL4 fusion proteins and
TRAP/Mediator complex), 5 fil (-50 [ig of total proteins)
of HeLa nuclear extract, 35 ng of each supercoiled
plasmid DNA template, 20 mM HEPES-KOH, pH7.9, 12%
(vol/vol) glycerol, 60 mM KCI, 4 mM MgCl2, 0.5 mg/ml BSA,
8 mM DTT, 0.5 mM ATP and CTP, 0.12 5 mM UTP, 0.1 mM 3'-0Met-GTP, 10 .uCi 32P UTP, 40 U of recombinant RNasin
(Promega), Activator and DNA templates were preincubated
at room temperature for 10 to 15 minutes followed by
addition of nuclear extracts and another 20 minuteincubation on ice. Transcription was initiated by
addition of NTPs and processed and analyzed as described.

In Vitro Transcription Assays reconstituted system with
purified factors.
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In vitro transcription assays with reconstituted

system

with purified factors were carried out essentially as
described previously (Malik et al., 2000). Transcription
reaction included the same components as described above
except 5 ng of TFIIB, 7.5 ng of TFIIE, 10 ng of TFIIF, 75
ng of PC4, TFIID equivalent to 2 ng of TBP, 2 0 ng of
TFIIH, 50 ng of RNA polymerase II instead of nuclear
extracts and other components (TRAP/Mediator and ERs) as
indicated. Activator and DNA templates were preincubated
at room temperature for 10 to 15 minutes followed by
addition of general transcription factors and another 2 0
minute-incubation on ice. Transcription was initiated by
addition of NTPs and processed and analyzed as described.

2.4. Materials and Methods for Chapter 6.

Antibodies and Western Blot Analysis.
Antibody against EDD/hHYD was kindly provided Dr. Watts
(Callaghan et al., 1998). Western blot analyses involved
standard procedures with an enhanced chemiluminescence
detection kit (Amersham) according to manufacturer's
instruction.
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In vitro translation of EDD/hHYD derivatives
35S-labelled various EDD/hHYD derivatives from the
constructs provided by Dr.Watts (Callaghan et al., 1998)
were expressed by TNT T7 coupled reticulocyte lysate
systems (Promega cat#L4610) according to manufacturer's
instructions.

Transient transfection assays.
Transfection was carried out using FuGENE 6 reagent
(Roche) according to manufacturer's instructions with
slight modification. CV1 and Ishikawa cells were plated
in 24-well plates (5xl04 cells/well) in phenol red-free
DMEM with 10% charcoal-stripped fetal calf serum. At the
following day, transfection was carried out using FuGENE
6 reagent (Roche) with 0.75 pq of DNA comprising 1-5 ng
of estrogen receptor expression vector, 250 ng of
luciferase reporter vector, and indicated amount of the
plasmids containing EDD/hHYD full-lenth or empty vector
and pRL-CMV for internal control. After incubation at 37
°C for 5 hours cells were treated with either E2 or
carrier. After another 36 hours cells were harvested and
assayed for luciferase activity by Dual Luciferase Assay
system (Promega) according to manufacturer's instruction.
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Chapter

3

Identification of ER-interacting Proteins
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3.1.

Introduction

Due to the clinical and physiological importance of
estrogen and SERMs, the molecular mechanism of ERmediated gene expression has received increased attention
and becomes one of the most studied subjects. As a
result, many diverse molecular mechanisms of ER-mediated
gene expression have been suggested and numerous factors
have been shown to be involved in those processes (see
above). In 1994, an apparent involvement of cofactors in
ER function emerged from the discovery of ERAPs (Halachmi
et al., 1994). In 1996, the striking discovery of the
second ER, which is encoded by a different gene and
exhibits dissimilarity with ERa in many aspects including
its primary structure (Kuiper et al., 1996), revealed
another layer of complexity of ER action and led to a
reevaluation of ER action in estrogen signaling.
Although the mechanisms that regulate ER functions
appear to be complex and diverse, they eventually could
be integrated into one that modulates the communication
properties of ERs. Given that ERs, as components of huge
multiprotein transcription machinery, communicate with
other factors via direct and/or indirect interactions,
the actions of ER is the result of the interplay by all
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the factors that are involved. The primary factors that
mediate and modulate this communication process, by
integrating the different signals and diversifying the
regulatory controls, are thought to be cofactors (see
above). In support of this notion, the first crystal
structures of ERa LBD complexed with E2 and RAL
demonstrated that a discrete class of ligands induced
distinct conformations in the AF-2 domain that is
responsible for interaction with cofactors (Brzozowski et
al., 1997). This suggested that the discrete properties
of ligands, through characteristic structures of ERs,
eventually led to the modulation of interactions with
cofactors.
Taken together, I set up the hypothesis that ERs
might recruit different repertoires of ER-interacting
proteins (presumptive cofactors) depending on the
ligands, the subtypes of ERs, and the cell/tissue types.
Furthermore, this different repertoire of ER-interacting
proteins could be one of the primary mechanisms to impose
specificity of ER-mediated gene expression and eventually
to explain the actions of SERMs.
Here I describe my attempt to identify and compare
the repertoire of nuclear proteins that interact with ERs
depending on ligand, subtypes of ER and cell-types. I
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employed GST pull down assays based on two earlier
successful studies with nuclear receptors that: 1)
identified ER interacting proteins such as ERAP 160 and
ERAP 140 depending on the ligand (Halachmi et al., 1994)
and 2) identified large groups of proteins such as DRIP
complex (Rachez et al., 1998). To examine the subtype
specificity, I decided to use GST-fused ERa full-length
and GST-ER(3 full-length. The rationale for employing the
full-length proteins was not only to detect both AF-1and AF-2- interacting proteins but also to avoid a simple
reproduction of the previous report (Halachmi et al.,
1994). In an effort to examine cell-type specificity, I
chose three representative cell lines: an MCF-7 breast
cancer cell line in which TAM works as an antagonist,
Ishikawa endometrial cancer cells in which TAM works as
an agonist, and HeLa uterine cervical cell line as an ER
negative cell.
In this study, there seemed to be no major
significant differences among three cell-types in the
overall electrophoresis migration patterns of
polypeptides interacting with GST-ERa LBD and GST-ER(3
full-length in the presence of E2. A number of HeLa
nuclear proteins interacting with GST-ER LBDs in the
presence of E2 were isolated and identified. These
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included TRAP/Mediator complex, which bound to both GSTERa LBD and GST-ER(3 LBD and several other proteins, which
bound exclusively to GST-ERa LBD independently of
TRAP/Mediator.

3.2. Results

3.2.1. Purification of ER interacting proteins
The GST and GST-fused ERa full-length, ERa LBD
(residues 302-595) and GST-ER(3 full-length were
expressed, purified and immobilized on glutathioneSepharose beads as described in the Materials and
Methods. After incubation with nuclear extracts derived
from MCF-7 (Fig. 3-1A) or Ishikawa (Fig. 3-1B) or HeLa
(Fig. 3-1C) cells in the presence or absence of 1 \xK E2,
beads were washed extensively and bound proteins eluted
and analyzed by SDS-PAGE followed by silver staining.
As shown in Fig 3-1, a large number of polypeptides
(circa 30 to 40 in each case) were found to interact with
GST-ERa LBD and GST-ER(3 full-length in the presence of 1
uM E2 (lanes 4 and 9 in Fig. 3-1A and 3-1C, lanes 4 and 8
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Fig. 3-1. E2-dependent interactions of nuclear extract
proteins with ERa full-length, ERa LBD and ER(3 fulllength. Nuclear extracts were derived from MCF-7 (A),
Ishikawa (B) and HeLa (C) cell lines. Immobilized GST
(lanes 1 and 2), GST-ERaLBD (lanes 3 and 4) and GSTERpLBD (lanes 8 and 9 in A and C, lanes 7 and 8 in B)
proteins were incubated with nuclear extract in the
absence (-) or presence ( + ) of 1 fxM E2 and bound proteins
were eluted and analyzed by SDS-PAGE and silver staining
as described in Materials and Methods. Purified
TRAP/Mediator complex from f:Nut2 expressing cells was
analyzed in lane 5 in A and C.
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in figure 3 - 1 B ) . There were a number of polypeptides
interacting with GST-ERa LBD and GST-ER(3 full-length in
the absence of E2 (lanes 3 and 8 in Fig. 3-1A and 3-1C,
lanes 3 and 7 in figure 3-1B), but most of them appeared
with the GST alone and thus appeared to be nonspecific.
The results of the GST-pull down assays with GST-ERa
full-length were not easy to interpret clearly- This was
most probably due to the degradation of GST-ERa fulllength proteins, which was seen in the isolated GST-ERa
full-length proteins alone.
Regarding cell-type specificity, there seemed to be
no major significant difference among three cell-types in
the overall electrophoretic migration pattern of the
prominent polypeptides interacting with GST-ERa LBD in
the presence of E2 (see below for the detailed
description in case of HeLa). However, the further
analyses are required to establish cell-type dependent
differences in the identity of these polypeptides.
Although there appeared to be some variations depending
on the cell types in the absence of ligand, these were
most likely due to slight variations in the amounts of
GST fused proteins used in each this particular
experiment. Again, this also needs to be clarified by
further studies.
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Concerning subtype specificity, direct comparisons
were not possible due to difficulty in interpreting the
results with the GST-ERa full-length. However, comparison
of the results with GST-ERa LBD and GST-ER(3 full-length
revealed that circa twenty polypeptides were found to
interact with both GST-fused proteins in the presence of
E2 although they showed stronger interactons with GST-ERa
LBD than with GST-ER(3 full-length. Interestingly, there
were circa 15 polypeptides bound, seemingly specifically,
to GST-ERa LBD in the presence of E2. The results with
GST-ERa LBD were different from the previous reports
using a similar assay identified either only two proteins
or almost nothing (Halachmi et al., 1994; Rachez et al.,
1998). This difference might be due to different
constructs of GST-ERa LBD [302-595 in this study v.s.
312-595 in the previous study (Rachez et al., 1998)] and
probable variation of assay condition [although I
followed the procedure as described previously (Rachez et
al., 1998)]. For further characterization of this
preliminary result, I decided to use HeLa nuclear extract
because of practical reasons and GST-ER LBDs because of
the failure to get clear results with the GST-ERa fulllength. Thus, I generated a corresponding ER(3 LBD
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(residues 243-530) fused to GST to compare with the GSTERa LBD for receptor subtype specificity.

3.2.2. A number of nuclear proteins interact with ER
To characterize the proteins bound to GST-ER LBDs,
GST-pull down assays were carried out essentially as
described above except GST-fused ERa (residues 302-595)
and ER(3 (residues 243-530) LBDs were used with HeLa
nuclear extract in the presence and absence of E2.
As shown in Fig. 3-2, circa 5 proteins bound
specifically but quite weakly to GST-ERa LBD (lane 3) and
circa 10 proteins bound specifically but weakly to GSTER(3 LBD (lane 7), relative to GST alone, in an E2independent manner (lanes 3 and 7); and these proteins
largely (but not completely) overlapped for ERa and ER(3.
Much larger groups of proteins (circa 30-40 in each
case) showed E2-dependent interactions with the GST-LBDs
(lanes 4 and 6) and these also largely (but not
completely) overlapped for ERa and ER(3. Many of the
polypeptides commonly associated with both GST-ER LBDs in
the presence of E2 appeared similar in size to components
of the circa 25-subunit TRAP/Mediator complex. This was
further indicated by a direct comparison of the
independently purified TRAP/Mediator complex (which
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Fig. 3-2. E2-dependent interactions of HeLa nuclear
extract proteins with ERa and ER(3 LBDs. Immobilized GST
(lanes 2 and 8), GST-ERaLBD (lanes 3 and 4) and GSTERI3LBD (lanes 6 and 7) proteins were incubated with HeLa
nuclear extract in the absence (-) or presence (+) of 1
U.M E2 and bound proteins were eluted and analyzed by SDSPAGE and silver staining as described in Materials and
Methods. Purified TRAP/Mediator complex from f:Nut2
expressing cells was analyzed in lane 5. Standard
molecular weight markers with sizes in kDa indicated on
the left were present in lane 1. Bands marked with an
asterisk represent degradation products of GST-ER fusion
proteins.
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contains some polypeptides that non-specifically bind to
M2 agarose; and lane 2 in Fig. 4-8A) and subsequent
analysis of TRAP/Mediator subunit interactions with the
LBDs by western blot (see chapter 4).
To further identify other prominent proteins
interacting seemingly specifically with GST-ERa LBD in
the presence of E2, mass spectral analyses was employed
in collaboration with Wenzhu Zhang, at the laboratory of
Brian Chait. Wenzhu Zhang characterized most of the
polypeptides interacting with GST-ERa LBD in the presence
of E2. These analyses confirmed the presence of specific
TRAPS (e.g. TRAP220, TRAP170, hSUR2, PAQ/TIG1, TRAP95,
TRAP80, p37, p36, MED6 and hSOHl) and further revealed
many other known proteins as detailed in Figure 3-3.

3.2.3. TRAP/Mediator-independent population(s) in ER LBDinteracting proteins
The observation of variations in stoichiometry of
ER-LBD interacting proteins and the existence of
TRAP/Mediator as one biochemically stable complex (Gu et
al., 1999) hinted at their independent binding to ER
LBDs. However, the simultaneous interaction of these
proteins with GST-ERa LBD raised questions regarding the
possible cooperativity in their interactions and
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Fig. 3-3. Composition of E2-dependent ERa LBD-interacting
proteins. Identity of proteins is determined by mass
spectral analysis.
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functions: 1) Does TRAP/Mediator interact with GST-ERa
LBD directly or through other proteins in the total
population or vice versa? ; 2) Is the interaction of
TRAP/Mediator enhanced by other proteins in the
population or vice versa? Independent binding rather than
interdependent binding was suggested by further analyses
showing a direct physical interaction between ERs and
TRAP/Mediator complex (see below). However, this did not
exclude the possibility of an essential role for
TRAP/Mediator in the interaction of the other population
of the proteins with GST-ERa LBD. This question was
solved partly by the GST-pull down assays with nuclear
extracts derived from wild type (WT) and TRAP220"/" mouse
embryo fibroblasts (MEFs) that were originally isolated
to assess the role for TRAP220 (see below).
As shown in Fig. 3-4, the overall electrophoretic
migration patterns of the murine polypeptides interacting
in the presence of E2 with GST-ERa LBD from WT MEF
nuclear extracts was very similar to that of the human
ones (lane 3 in Fig. 3-4 vs lane 4 in Fig.3-2). This was
confirmed by mass-spectral analyses by Wenzhu Zhang. The
analyses with TRAP220-/- MEF-derived nuclear extracts
revealed that most of the polypeptides other than
TRAP/Mediator retained on GST-fused ER LBDs in an E2-
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Fig. 3-4. TRAP/Mediator-independent interactions of
proteins with ER LBDs in nuclear extract. Immobilized GST
(lanes 1 and 12), GST-ERa LBD (lanes 2, 3, 5, and 6) and
GST-ER(3 LBD (lanes 7, 8, 10,11) were incubated with the
nuclear extracts from wild type (WT) (lanes 1, 2,3,7 and
8) and TRAP22 0~/~(KO) MEFs (lanes 5,6,10,11 and 12) in the
absence (-) or presence ( + ) of 1 |a,M E2 and bound proteins
were eluted and analyzed by SDS-PAGE and silver staining
as detailed in Materials and Methods. TRAP/Mediator
complexes immunopurified from cells expressing f:Nut2 are
shown lanes 4 and 9.
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dependent manner, thus indicating that these polypeptides
bound to GST-ER LBDs independently of TRAP/Mediator
complex. Moreover, the observation that the intensity of
the interaction was not affected by the absence of
TRAP/Mediator complex also suggested independent binding
rather than cooperativity.
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Chapter

4

The TRAP/Mediator Coactivator Complex Interacts
Directly with ER a and ER |3 and Directly Enhances ER
Function In Vitro
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4.1. Introduction

As mentioned in chapter 3, as a part of a broader
effort to identify novel ER-interacting factors
(presumptive cofactors) that might show specificity for
ERa and (3 subtypes and/or mediate tissue selective
functions of SERMs (reviewed in McDonnell, 1999), I found
E2-dependent interactions of the complete TRAP/Mediator
complex with both ERa and ER(3.
TRAP/Mediator complex was first identified through a
ligand-dependent intracellular association with thyroid
hormone receptor (TR) and shown to be essential for TR
function on DNA templates in a reconstituted cell free
system (Fondell et al., 1996). Subsequent isolation of
the DRIP complex, apparently identical to TRAP/Mediator
complex, extended its specificity for VDR through a
ligand-dependent interaction with GST-VDR LBD (Rachez et
al., 1998). However, the functional involvement of
TRAP/Mediator complex in the action of class I (steroid
hormone) nuclear receptors was not as well established as
class II nuclear receptors such as TR and VDR. Despite
the strong body of evidence indicating the significance
of TRAP220 subunit in ER function (see below), it was
suspected that ER might not interact with or coactivate
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through intact TRAP/Mediator complex because of the
following; (1) a failure to detect interaction of DRIP
complex with ERaLBD in their GST-pull down assays (Rachez
et al., 1998), (2) subsequent failures to demonstrate the
interaction between ERs and the intact TRAP/Mediator
complex by Freedman and his colleagues (Burakov et al.,
2000) and by Chao-Xing Yuan (unpublished observation)
using immunoaffinity purification assays from the cell
lines expressing epitope tagged ER alpha. In fact, one of
the latter studies suggested that ER might function
through TRAP220 alone or through a different TRAP220
(sub)complex (Burakov et al., 2000).
The study described here firmly established the role
for the intact TRAP/Mediator complex in ER dependent
transcription by showing that the interactions between
TRAP/Mediator and ERs are direct and dependent on the ER
LBD (but apparently modulated by the AF-1 domain) and
that TRAP/Mediator can directly facilitates ER function
in a cell-free system. This was the first report on the
functional involvement of the intact TRAP/Mediator
complex in the actions of class I (steroid hormone)
nuclear receptors and further supported the notion that
TRAP/Mediator is the general cofactor.
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4.2. Results

4.2.1. Estrogen-dependent Interactions of TRAP/Mediator
with ER LBDs in Nuclear Extracts
To extend the analyses of Fig. 3-2, proteins bound
to ER LBDs in the presence and absence of E2 were
analyzed by western blot with antibodies to a more
comprehensive set of TRAP/Mediator components. As shown
in Fig. 4-1, and by comparison with purified TRAP
(f:Nut2) and TR-TRAP (f:TR) complexes, all TRAP/Mediator
components examined (other than TRAP150, which may not be
a bona fide integral subunit) were found to associate
with ERa and ER(3 LBDs in an E2-dependent manner. As
equimolar amounts of immobilized fusion proteins were
used for the binding assays, the results also confirmed a
stronger interaction of TRAP/Mediator complex with the
isolated ERa LBD than with the isolated ER(3 LBD. The
assays in Fig.4-1 further showed ligand-dependent
interactions of SRC-1 and p300 with ER LBDs. As observed
for TRAP/Mediator, these interactions are stronger for
ERa than for ER|3. Consistent with the results of our
previous analyses of TRAP/Mediator complexes (Gu et al.,
1999; Malik et al., 2000), and indicative of specificity
of factor binding to ER LBDs, no interactions of general
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Fig. 4-1.

E2-dependent interactions of TRAP/Mediator

with ERa and ER(3 LBDs in nuclear extract. Immobilized GST
(lane 2), GST-ERaAB (lane 3), GST-ERaLBD (lanes 4 and 5),
GST-ERf3AB (lane 6) and GST-ER|3LBD (lanes 7 and 8)
proteins were incubated with HeLa nuclear extract in the
absence (-) or presence ( + ) of 1 uM E2 and bound proteins
were eluted and analyzed by SDS-PAGE and western blot
(with antibodies to proteins indicated on the left) as
described in Materials and Methods. One-tenth equivalent
of the input nuclear extract is shown in lane 1.
TRAP/Mediator and TR-TRAP complexes immunopurified from
cells expressing f:Nut2 and f:TR respectively, are shown
lanes 9 and 10. The band observed in lane 6 with MED7
antibody is a nonspecific band that cross-reacts with
this antibody.
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transcription factors TFIIE (IIEa) and TFIIF (RAP30) were
observed.
Also of note is the lack of any detectable binding
of TRAP/Mediator components to GST-fused ERaAB and ERpAB
regions that contain the AF-1 domains (Fig. 4-1). This is
consistent with the observation that the isolated TRAP220
showed no detectable interaction with ER AF-1 but with ER
AF-2 (Burakov et al., 2000). This result contrasts with
reports that other nuclear receptor coactivators,
including pl60/SRC members, can interact not only with
AF-2 domains in a ligand-dependent manner but also with
AF-1 domains in a ligand-independent manner (Webb et al.,
1998). It is notable, however, that in our assays
interactions of these components (at normal nuclear
levels) with ERaAB and ER(3 AB domains were either
undetectable (p300) or barely detectable (SRC-1). The
inability to see TRAP/Mediator interactions with AB
domains also contrasts with the demonstration of a
ligand-independent interaction of independently expressed
TRAP170 with the AF-1 domain of the glucocorticoid
receptor (Hittelman et al., 1999). However, these results
do not exclude possible modulatory effects of AB and
associated AF-1 domains on interactions of TRAP/Mediator
with LBD and associated AF-2 domains.
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4.2.2. Direct Interactions of Purified TRAP/Mediator
complex with ER LBDs
The studies described above have clearly shown
ligand-dependent interactions of TRAP/Mediator with ER
LBDs but, since they utilized nuclear extracts as a
source of TRAP/Mediator, did not establish whether other
factors were essential for these interactions. To further
investigate this question, I employed a highly purified
TRAP/Mediator complex immunopurified from cells
expressing a FLAG-tagged SRB10/CDK8 subunit (Gu et al.,
1999). As shown in Fig. 4-2, this complex showed an E2dependent interaction with the ERa LBD and an E2-enhanced
interaction with the ER(3 LBD. Overall interactions in the
presence of E2 were again stronger for ERa than for
ER|3, as in the analyses with nuclear extracts (above).
Although I do not know the basis for the decreased
ligand-dependency of the ER(3 LBD interaction with
purified TRAP/Mediator, relative to TRAP/Mediator in
nuclear extracts (above), this may reflect the absence of
negative constraints (interacting factors) that increase
the ligand-dependency of interactions in nuclear
extracts. This observation is also consistent with the
observation of ligand-dependent interactions of ER(3 with
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Fig. 4-2. Direct interactions of purified

TRAP/Mediator

with LBDs of ERa and ER(3. Immobilized GST (lanes 6 and
7), GST-ERa LBD (lanes 2 and 3) and GST-ER(3 LBD (lanes 4
and 5) were incubated with immunopurified TRAP/Mediator
complex from cells expressing f:CDK8/SRB10 in the absence
(-) or presence ( + ) of 1 \xM E2. After extensive washing,
bound proteins were eluted and analyzed by SDS-PAGE and
western blot (with antibodies to proteins indicated on
the left) as described in Materials and Methods. Onetenth equivalent of the input TRAP/Mediator preparation
was analyzed in lane 1.
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Fig. 4-3. Intracellular association of TRAP/Mediator with
ERaAAB. C8 cells that express FLAG-tagged ERa lacking the
AB domain (f:hERaAAB) were maintained in DME-P04 media
supplemented with 10% calf serum, f:ERaAAB and associated
proteins were affinity-purified from C8-derived nuclear
extract on M2 agarose. Proteins bound in the presence
( + ) or absence (-) of 1 uM E2 during purification were
eluted with FLAG peptide and analyzed by SDS-PAGE and
western blot with antibodies to proteins indicated on the
left. M2 agarose-bound proteins from HeLa extract were
analyzed in lane 1 and one-tenth equivalent of C8 nuclear
extract input was analyzed in lane 4.
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a TRAP220 fragment in gel shift assays (Warnmark et al.,
2001).

4.2.3. Intracellular Association of TRAP/Mediator with
ERaAAB
To provide evidence for a physiological association
of ER with TRAP/Mediator, as previously demonstrated for
TR (Fondell et al., 1996), I isolated FLAG-tagged ERaAAB
(f:hERaAAB) and associated proteins through affinitypurification from C8-derived nuclear extracts on M2
agarose beads. The C8 cell line, established by Chao-Xing
Yuan, is a HeLa-derived cell line that stably expresses a
FLAG-tagged ERa lacking the AB domain (ERaAAB). A western
blot of the bound and eluted proteins revealed the
presence of FLAG-tagged ERaAAB (scored by both ERa and
FLAG antibodies) as well as all TRAP/Mediator components
that were analyzed (Fig. 4-3). An intracellular
association of ERaAAB with p300 was also detected. None
of these proteins were bound to M2 agarose when a control
extract from HeLa cells was applied. These results thus
indicate an intracellular association of the entire
TRAP/Mediator complex with ER, as originally described
for TR.
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In the current analysis the probable E2-dependence
of this association could not be assessed, as the C8
cells lost receptors and exhibited poor viability in
steroid-depleted media; and while purification of the
ERaAAB-containing complex in the presence and absence of
E2 yielded comparable results (Fig. 4-3, lane 2 vs. lane
3), this likely reflects prior occupancy and stability of
the ER ligand binding pocket by estrogen or estrogen-like
compounds in the culture media.

4.2.4. Roles for TRAP/Mediator In ER Function In nuclear
extract.
TRAP/Mediator has been shown to enhance the transcription
activity of several activators, including nuclear
receptors, from DNA templates in purified cell free
systems (Fondell et al., 1996; Gu et al., 1999; Ito et
al., 2000). To assess the role of the complete
TRAP/Mediator complex in ER-mediated transcription, I
employed a cell free system with TRAP/Mediator depleted
nuclear extracts provided by Hwa Jin Baek (Baek et al.,
2002), combinations of baculovirus-expressed and purified
GAL4-ER LBDs consisting of the DNA binding domain of the
yeast activator GAL4 fused to the ER LBD (Fig.4-4) and
affinity purified TRAP/Mediator from f:Nut2-derived
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Fig. 4-4. Recombinant FLAG-tagged GAL4-ER LBD proteins.
Affinity purified GAL4-ER LBD proteins were analyzed by
SDS-PAGE and by either Coomassie Brilliant Blue R-250
staining (left panel) or western blot with anti-FLAG
antibody (right panel).

113

Recombinant G A L 4 - E R

tr

tr

L B D

tr

proteins

tr

* #

c o o m a s i e staining

western blot

nuclear extract and a DNA template containing five copies
of an GAL4 binding sites upstream of the adenovirus major
late core promoter (Kundu et al. , 2000). The rationale
for this approach was: 1) a previous study showing that
GAL4-fused ERa LBD activates transcription in a liganddependent manner in cell-based assays (Webster et al.,
1988); 2) the previous studies showing the function of ER
in an in vitro transcription assay using GAL4-fused ERa
LBD in conjuntion with crude nuclear extracts from naked
DNA templates (Webster et al., 1988; Jacq et al., 1994)
in contrast to the failure of full-length ER proteins in
the same system (unpublished observation by myself and
Chao-Xing Yuan); and 3) previous studies assessing the
activity of TRAP/Mediator in a depleted nuclear extract
system presumably containing a more normal complement of
nuclear factors (Baek et al., 2002). In this assay (Fig.
4-5), GAL4-ERa LBD (lanes 1 and 2) activated
transcription weakly (circa 2-fold) and GAL4-ER(3 LBD
(lanes 8 and 9) activated circa 4-fold in untreated
nuclear extracts. By contrast, in the TRAP/Mediatordepleted nuclear extract (ATRAP/MED) the absolute levels
of activated transcription were completely reduced to the
basal level (lanes 3 and 4, and lanes 10 and 11). Also of
note, the levels of basal (activator-independent)
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Fig. 4-5. Requirement of TRAP/ Mediator for
transcriptional activity of GAL4-ER LBDs in nuclear
extract. Transcription activation by GAL4-ER LBDs is
suppressed in the a-TRAP25 antibody-depleted nuclear
extract. In vitro transcription reactions contained 20 \xq
each nuclear extract (lanes 1,2,8,9: untreated; lanes 37,10-13: a-TRAP25 antibody-depleted) and 50 ng each of
pA53 and pG5A53 templates, respectively. The
transcription reactions in lanes 1-7 and lanes 8-13
additionally contained 10 ng of recombinant GAL4-ERa LBD
and GAL4-ER(3 LBD respectively. Increasing amount of
purified TRAP/ Mediator (lanes 5-7 and lanes 12,13) were
added to a-TRAP2 5 antibody-depleted nuclear extract in in
vitro transcription reactions. As determined by
immunoblotting, the amount of TRAP/ Mediator added to the
reactions corresponded to approximately 100 % (lanes
5,12) or 200 % (lanes 6,13) or 400 % (lane 7) of the of
the TRAP/ Mediator concentration in untreated nuclear
extract. Relative transcription levels, determined by
phosphorimaging, are indicated.
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(lanes 1 vs.3 and lanes 8 vs.10) were

decreased upon depletion of TRAP/Mediator as reported
previously (Baek et al., 2002). Upon addition of
increasing amounts of TRAP/Mediator to depleted extract,
activated transcription was, in a dose-dependent manner,
enhanced up to seven-fold in the case of GAL4-ERa LBD and
up to twenty-fold in the case of GAL4-ER(3 LBD. This
indication that an excess amount of ectopic TRAP/Mediator
can enhance activated transcription by GAL4-ER LBDs
beyond the level seen in the control extract suggests
that TRAP/Mediator is a limiting cofactor for ER
function. These results clearly demonstrated a role for
TRAP/Mediator in ER-LBD function, as well as a greater
activity for ER(3 LBD than for ERa LBD (lanes 2 vs. 9 and
lanes 6 vs.13). In addition, the relative responses of ER
LBDs to the ectopic TRAP/Mediator correlate with the
intrinsic affinity of ER LBDs for TRAP/Mediator.

4.2.5. Interactions of TRAP/Mediator with Intact ERs.
The above results have established E2-dependent
interactions of TRAP/Mediator with isolated ER LBDs, but
these interactions can be considered physiologically
relevant only if they are demonstrable in the context of
natural full-length receptors. In an analysis of this
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question, full-length FLAG-tagged ERs were expressed via
baculovirus vectors, affinity purified and immobilized on
M2 agarose beads (Fig.4-6). Nuclear extracts were applied
to beads containing immobilized receptors, and after
washing bound proteins were eluted and analyzed by SDSPAGE and western blotting with antibodies to
representative TRAP/Mediator components. As indicated in
Fig. 4-7, TRAP/Mediator bound to both ERa and ER(3 in an
E2-dependent manner. However, in contrast to the results
with ER-LBDs, TRAP/Mediator showed stronger interactions
with ER(3 than with ERa. Although not directly comparable,
these results are nonetheless consistent with a prior
report that isolated TRAP220 interacts more strongly with
intact ER(3 than with ERa (Warnmark et al., 2001). Given
that the assays for TRAP/Mediator interactions with
intact ERs (Fig.4-7) versus ER LBDs (Fig. 4-1) were
performed under comparable conditions, these results
suggest that the ERa and ER(3 AB domains differentially
modulate interactions of TRAP/Mediator with corresponding
LBDs.
To investigate the possibility that additional
nuclear proteins might have facilitated intact ERTRAP/Mediator interactions in these assays, the binding
of 35S-labelled full length ER(3 to purified and
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Fig. 4-6. Recombinant FLAG-tagged ER proteins. Affinity
purified ERs were analyzed by SDS-PAGE and by either
Coomassie Brilliant Blue R-250 staining (lanes 1 and 2)
or western blot with corresponding antibodies (lanes 3
and 4).
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Fig. 4-7. E2-dependent interactions between TRAP/Mediator
and ERs in HeLa nuclear extract. M2 agarose-immobilized
FLAG-ERa (lanes 3 and 4) and FLAG-ER(3 (lanes 5 and 6) were
incubated with HeLa nuclear extracts in the absence (-)
or presence ( + ) of 1 u.M E2 and bound proteins were eluted
with FLAG peptide and analyzed by SDS-PAGE and western
blot (with antibodies to proteins indicated in the left)
as described in Materials and Methods. As a control, HeLa
nuclear extract proteins bound to M2 agarose alone were
analyzed in lane 2. One-tenth of input nuclear extract
was analyzed in lane 1.
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(Fig.4-8A) was analyzed. For

technical reasons relating to the presence of FLAG tags
both on recombinant ERs and on the purified TRAP complex,
an analysis of TRAP/Mediator binding to M2 agaroseimmobilized ERs was not possible. As shown in Fig. 4-8B,
35S-labelled full length ER(3 bound to purified
TRAP/Mediator, thus indicating direct ER-TRAP/Mediator
interactions.

4.2.6. TRAP/Mediator Directly Enhances ER Function In a
Purified In Vitro Transcription Assay.
TRAP/Mediator has been shown to enhance the
transcription activity of several activators, including
nuclear receptors, from DNA templates in purified cell
free systems (Fondell et al., 1996; Gu et al., 1999; Ito
et al., 2000). The role of the complete TRAP/Mediator
complex in ER-mediated transcription, was further
assessed, in collaboration with Mohamed Guermah, in a
cell free system reconstituted with highly purified
general initiation factors and cofactors (TFIIB, TFIID,
TFIIE, TFIIF, TFIIH, RNA polymerase II and PC4),
combinations of baculovirus-expressed and purified
receptors (Fig.4-6) and affinity purified TRAP/Mediator
(Fig.4-8A lane 2), and a DNA template containing four
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Fig. 4-8. E2-dependent interactions between purified
TRAP/Mediator and full-length ER|3. A. Purified
f:TRAP220AB TRAP/Mediator complex. The complex was
affinity purified from cells expressing a FLAG-tagged
TRAP2 2 0 lacked the C-terminal domain (f:TRAP2 2 0AB) and
analyzed by SDS-PAGE and silver staining (lane 2). Lane 1
shows HeLa nuclear extract proteins bound nonspecifically to M2 agarose. B. Direct interactions
between purified TRAP/Mediator complex and full-length
ER(3. M2 agarose immobilized TRAP/Mediator (f :TRAP2 2 0AB)
complex (lanes 3,4 and 6) and M2 agarose alone (lanes 2
and 5) were incubated with 35S-labeled (in vitro
translated) full length ER(3 in the presence (lane 3) or
absence (lane 4) of 1 \xM E2 or with control lysate (lanes
5 and 6). After washing, bound proteins were eluted with
FLAG peptide and analyzed by autoradiography (upper
panel) or by western blot with antibodies to the
indicated components of TRAP/Mediator complex (lower
panel). Lane 1 shows one-twentieth of the 35S-labeled full
length ER(3 input.

125

E 2 - d e p e n d e n t interactions

b e t w e e n

purified TRAP/Mediator and full-length ER(3

|

O
<N

CQ
<
o
CM
<N

4-1
3 CM
a. 2
c

M2 ^

E 2 (1 u M )
35s.ERp

+

I

I

+

-

+

+

wm
;0M».

TRAP230
. .,,
.
,..,.

control
I i
i
f:220AB

dq

ERP

M2

A
<

r»
B

hSUR2

t
-mm- rn^m

—,

HMWW I".-

___

.^t J^^mti

FLAG
m

MED6

1 2

_

•

^mm..

SRB7

3

,

4

—

—

copies of an estrogen response element (ERE) upstream of
the adenovirus major late core promoter (Wu et al.,
1999). In this assay (Fig. 4-9), basal activity (lane 1)
was unaffected by ERa alone (lane 3) and weakly (circa
2-fold) enhanced by ER(3 alone (lane 4) or by
TRAP/Mediator alone (lane 2). In the presence of
TRAP/Mediator, activity with ERa was about five-fold
above basal (lane 5) and activity with ER(3 was about 20fold above basal (lane 6). These results clearly show a
direct role for TRAP/Mediator in ER function, as well as
a greater activity for ER(3 than for ERa as the equimoloar
amounts of ERs were used for this assay. While somewhat
surprising, the latter result is consistent with the
higher affinity of TRAP/Mediator for intact ER(3 relative
to intact ERa considering the fact that ERa showed the
stronger DNA binding activity than ER(3 (data not
included).
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Fig. 4-9. TRAP/Mediator complex directly mediates ER
function in vitro. Reactions contained purified general
transcription factors and cofactors, purified
TRAP/Mediator complex and ER proteins (20 nM) as
indicated, and both 4EREA53 G-less reporter and ML200 Gless control templates. TRAP/Mediator was purified from
the cell line expressing f:TRAP220AB (Fig. 4-8A lane 2).
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Chapter

5

Role of TRAP220 subunit in ER Function
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5.1.

Introduction

The significance of TRAP220 subunit in Nuclear
receptor function has been well established by studies
showing: 1) original isolations through its direct
interaction with TR (Lee et al., 1995) and PPARy(Zhu et
al., 1997) in yeast two-hybrid assays; 2) liganddependent interactions of TRAP22 0 with a number of other
nuclear receptors, further suggesting a broader role for
TRAP2 2 0 through TRAP/Mediator in nuclear receptor
function (Yang et al., 2000; Rachez et al., 1999; Yuan et
al., 1998 ; Zhu et al., 1997); 3) defective cellular
functions of various receptors in response to dominant
negative mutant form of TRAP220 (Yuan et al., 1998; Zhu
et al., 1997); 4) significant physiological defects
including receptor function upon deletion of TRAP220 (Ito
et al., 2000; Shao et al., 2000; Zhu et al., 2000; Ge et
al., 2002).
Despite the lack of any direct evidence for the role
for the TRAP/Mediator complex in ER function, a number of
studies suggested the potential involvement of TRAP220
subunit in ER function. Chao-Xing Yuan first observed a
ligand-dependent interaction of intact TRAP22 0 with ERa
although it was very weak compared to other receptors
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(Yuan et a l . , 1998). Subsequent studies confirmed
physical interactions of TRAP220 with ERa (Burakov et
al., 2000; Warnmark et al., 2001; Zhu et al., 1999),
demonstrated inhibitory effects of an ER-interacting
fragment of TRAP220 (Burakov et al., 2000) and an antiTRAP220 antibody on ERa function in transfected cells,
and established the presence of TRAP220 on the promoters
of endogenous estrogen-responsive genes (Shang et al. ,
2000). However, interpretation of these studies was
complicated by (1) the stable association of TRAP220 with
other TRAP/Mediator components that may mediate (via
different activators not ER) TRAP/Mediator recruitment
and function; (2) the failure to analyze suitable control
genes and other cofactors for broader effects of agents
designed to block TRAP220 functions; and (3) some
discrepancy regarding the ability of TRAP220 to interact
with ERa vs. ER(3 (mentioned in Kang et al., 2002).
Not surprisingly, TRAP220 contains two LXXLL motifs
that are found in most of nuclear receptor cofactors and
responsible for the interaction with nuclear receptors.
The LXXLL motif has been suggested to play roles in
determining specificity from the observation that
different LXXLL motif is required for the interaction
with specific nuclear receptors. Consistent with this
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idea, the second (closer to C-terminal) LXXLL motif (NR
box2) in TRAP220/DRIP205 was essential for the
interaction with VDR and TR, whereas the first (more Nterminal) motif (NR boxl) was dispensible (Yuan et al.,
1998; Rachez et al., 2000).
Here I characterized a role for TRAP220 in ER
function. I showed that TRAP220 is an essential anchor
for a strong interaction between ER and TRAP/Mediator. I
further demonstrated that both NR boxes within TRAP2 2 0
are important for mediating an interaction between ER and
the TRAP/Mediator complex. I also describe my preliminary
studies on the function of TRAP220 and its NR boxes in
ER-dependent transcription.

5.2. Results

5.2.1. TRAP220-dependent Interactions of TRAP/Mediator
with ER LBDs in Nuclear Extracts.
The demonstration of ligand-dependent interactions
of ERa and ER(3 with isolated TRAP220 (Burakov et al. ,
2000; Warnmark et al., 2001; Yuan et al., 1998; Zhu et
al., 1999) and the observation that TRAP220 is a main
subunit for strong ligand-dependent interactions of the
TRAP/Mediator complex with nuclear receptors such as TR
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and VDR (Yuan et al., 1998; Rachez et a l . , 1 9 9 9 ) , has led
to speculation that TRAP2 2 0 may anchor ERs to the
TRAP/Mediator complex. To address this issue, I employed
GST pull down assays with nuclear extracts from MEFs
derived from wild type and TRAP220-/- mice (Ito et al.,
2000). This approach is technically simpler than other
alternative approaches such as a Far Western analysis
employed for TR (Yuan et al., 1998). The availability of
reagent further facilitated this assay. Furthermore, this
assay can determine the role for TRAP22 0 in the observed
ER-TRAP/Mediator interaction. As shown in Fig. 3-4 and
Fig.5-1, TRAP/Mediator components from control MEFs bound
in an E2-dependent manner to GST-fused ER LBDs whereas
TRAP/Mediator components from TRAP2 2 0-/- MEFs did not.
Other studies have shown that TRAP220-/-cells contain a
residual TRAP complex lacking only TRAP220 and that this
complex interacts normally with other activators such as
VP16 (Chao-Xing Yuan and Sohail Malik unpublished
observation). These results firmly establish an essential
role for TRAP220 in strongly anchoring TRAP/Mediator to
ERa and ER(3 and again show that TRAP/Mediator has a
stronger affinity for the isolated ERa LBD than for the
isolated ER(3 LBD in the context of other nuclear
proteins.
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Fig. 5-1. TRAP220-dependent interactions of TRAP/Mediator
with ER LBDs in nuclear extract. Immobilized GST (lanes 2
and 11), GST-ERa LBD (lanes 3-6) and GST-ER|3 LBD (lanes
7-10) were incubated with the nuclear extracts from wild
type (WT) (lanes 2,3,4,7 and 8) and TRAP22 0"/"(KO) MEFs
(lanes 5,6,9,10 and 11) in the absence (-) or presence
( + ) of 1 u.M E2 and bound proteins were eluted and
analyzed by SDS-PAGE and western blot (with antibodies to
proteins indicated on the left) as detailed in Materials
and Methods. One-tenth equivalents of input nuclear
extracts were analyzed in lanes 1 (WT) and 12 (KO).
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5.2.2. Effect of TRAP220 on ER-driven

transcriptional

activation in TRAP220/~ MEFs.
The essential requirement of TRAP220 for the ERTRAP/Mediator interaction raised the possibility that
loss of TRAP220 could result in the failure to support
ER-activated transcription. To examine this possibility,
I carried out transfection assays with WT and TRAP220-/MEFs employed in the previous pull down assays. MEFs of
each genotype were transfected with an ER expression
vector and a reporter containing three ERE sites and core
promoter. A strong E2 response (up to 80-fold induction)
was observed in wild type cells. The response was
attenuated only modestly (circa 2-fold), but very
reproducibly, in TRAP220-/- MEFs (Fig. 5-2).
Significantly, however, transcription in TRAP220-/- MEFs
was restored to the wild-type level by simultaneous
expression of ectopic TRAP220 (Fig. 5-3). While TRAP220
is essential for optimal ER function in response to E2,
the significant activation of ER-driven transcription in
TRAP220-/- MEFs that suggests the existence of an
alternative pathway(s) to support ER function or lack of
proper restraint, which TRAP/Mediator is required to
overcome (see discussion).
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Fig. 5-2. Defect in ER-mediated transcription in TRAP220"
/_MEFs. The MEFs of each genotype were transfected with
indicated amounts of human ER, 3ERE-luciferase reporter,
and control luciferase pRL-CMV. Cells were cultured in
the absence (-) or presence ( + ) of the ligand, E2 (IO"8
M), and dual luciferase activities were measured 36 hr
after transfection. Values (means ± SD of a
representative experiment performed in duplicate) are
plotted as a fold.
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Fig. 5-3. Complementation of defective ER-driven
transcription in TRAP220-/- MEFs by exogenous TRAP220.
The MEFs of each genotype were transfected with human ER,
TRAP220, 3ERE-luciferase reporter, and control luciferase
pRL-CMV. Cells were cultured in the absence (-) or
presence ( + ) of the ligand, E2 (10 nM) , and dual
luciferase activities were measured 36 hr after
transfection. Values (means ± SD of a representative
experiment performed in duplicate) are plotted as a fold.
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5.2.3. NR box-dependent Interactions of isolated TRAP220
with ER LBDs
The differential requirement of each NR box in
TRAP220 for the interaction with ERs had been suggested
by the previous observations that deletion or mutation of
NR1 in the fragment of TRAP220 (604-774) abolished or
decreased interaction with ERa while deletion or mutation
of NR2 (527-604) affected it to less extent (Burakov et
al., 2000; Warnmark et al., 2001). However, these results
can be considered physiologically relevant only if they
are demonstrable in the context of natural full length
TRAP220 and intact TRAP/Mediator complex. Prior to
addressing this issue in the context of intact
TRAP/Mediator complex, I examined the relevance of these
results in the context of the N-terminal part of TRAP22 0
(1-670), TRAP220 AB, on the basis of the following: 1)
TRAP220 is essential for demonstrable interaction of ER
with TRAP/Mediator; 2) availability of TRAP/Mediator
complexes containing TRAP2 2 0AB or each mutant derived
from TRAP220AB (right panel in Fig. 5-4); and 3) the
transcriptional activity of TRAP/Mediator complex
containing TRAP220AB to support TR function is equivalent
to that of TRAP/Mediator containing full-length TRAP220
(unpublished observation by Mohamed Guermah and Chao-Xing
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Y u a n ) . I employed GST pull down assays using GST-ER LBDs
with 35S-labeled proteins expressed from the constructs
(right panel in Fig. 5-4) harboring deletion mutants or
point mutants of TRAP2 2 0AB (provided by Chao-Xing Yuan).
Apart from TRAP220 NR mutants, I used various TRAP2 2 0AB
mutants in order to examine the possible involvement of
other part(s) of TRAP2 2 0 in the interaction between ER
and TRAP2 2 0 because the previous experiments used only
fragments of TRAP220 (Burakov et al., 2000). As shown in
Fig. 5-4, most of the mutants exhibited strong
interactions with GST-ER LBDs comparable to WT fulllength and AB fragment. In contrast, point mutations in
either NR box significantly diminished the TRAP220
interaction with ER LBD. Morevore, in contrast to the
results of previous reports (Burakov et al., 2000;
Warnmark et al., 2001), mutation in NR2 exhibited a more
severe effect than in NR1. This might be due to the
differences in assay conditions and/or TRAP220 constructs
that were used. In addition, the interaction between GSTER LBDs and TRAP2 2 0AB with the mutations in both NR boxes
was undetectable.
Also of note, ERa LBD and ER(3 LBD seemed to bind to
isolated TRAP220 similarly in this assay. This is
consistent with the earlier study by Burakov et al but is
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Fig. 5-4. NR box-dependent interactions of TRAP220 with
ER LBDs. Immobilized GST (lanes 6), GST-ERa LBD (lanes 2
and 3) and GST-ER^LBD (lanes 4 and 5) were incubated with
35S-labeled (in vitro translated) TRAP220 proteins in the
presence (lane 2 and 4) or absence (lane 3 and 5) of 1 [xM
E2 and bound proteins were eluted and analyzed by SDSPAGE followed by autoradiography as detailed in Materials
and Methods. Lane 1 shows one-seventh of the 35S-labeled
TRAP22 0 input.
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contrast to the study by Warnmark et al. More
importantly, this result seems to be contrast to the
result of many assays with nuclear extract and purified
TRAP/Mediator complex. Although we do not know the reason
yet this could be due to stimulatory effect of other
Mediator components on the interaction of TRAP2 2 0 with
ERa LBD and/or inhibitory effect on the interaction of
TRAP22 0 with ER|3 LBD.

5.2.4. NR box-dependent Interactions of purified
TRAP/Mediator with full-length ERp"
To analyze the observed role for the NR boxes in the
context of the intact TRAP/Mediator complex and intact
ER, I employed purified TRAP/Mediator complexes with
full-length ER(3. As shown in Fig 5-5, TRAP/Mediators
containing TRAP220a (NR1 mutant), TRAP220b (NR2 mutant)
or TRAP2 2 0ab (NR1/NR2 double mutant) (f:a, f:b and f:ab
respectively) all showed dramatic reductions (6-8 fold in
each case) in their interactions with full-length
ERp, compared to that of TRAP/Mediator complex containing
TRAP2 2 0AB (f:AB). This indicated that the point mutations
in either NR box significantly affect the interaction
between intact TRAP/Mediator and ER(3 full-length and
suggests that both NR boxes are important for the
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Fig. 5-5. TRAP220 NR box-dependent interaction between
purified TRAP/Mediator complex and full-length ER(3. M2
agarose immobilized TRAP/Mediator (f:TRAP220AB,
f:TRAP220a, f:TRAP220b and f:TRAP220ab) complexes (lanes
3,4, 5 and 6) and M2 agarose alone (lane 2) were
incubated with 35S-labeled (in vitro translated) full
length ER(3 in the presence (lanes 2-6) of 1 \xH E2. After
washing, bound proteins were eluted with FLAG peptide and
analyzed by autoradiography (top panel) or by western
blot with antibodies to the indicated components of
TRAP/Mediator complex (lower panels). Lane 1 shows oneseventh of the 35S-labeled full length ER(3 input.
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interaction between intact TRAP/Mediator and ER(3 fulllength.

5.2.5. Role for NR box of TRAP220 in ER-dependent
transcription in TRAP220-/- MEFs
To assess the role of the TRAP220 NR boxes in ER
dependent transcription I employed transfection assays
with MEFs previously utilized. MEFs of each genotype were
transfected with an ER expression vector, a reporter
containing three ERE sites with core promoter and
expression vectors for full length TRAP220 either wildtype or NR mutants. Simultaneous expression of ectopic
full-length TRAP220 restored to the wild-type level while
all the point mutants of TRAP220 did not (Fig. 5-6)
although the expression level of each TRAP220 was
comparable (data not included). This is consistent with
the results from the interaction study.

5.2.6. Role for NR box of TRAP220 in ER-dependent
transcription in cell free transcription assay
The observation of the modest defect in ER-driven
transcription in TRAP220-/- MEFs raised the concern that
this particular cell-based assay might not be able to
fully recapitulate normal ER activation mechanisms and
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Fig. 5-6. Role for TRAP 220 NR box in ER-driven
transcription. The MEFs of each genotype were transfected
with human ER, indicated TRAP220, 3ERE-luciferase
reporter, and control luciferase pRL-CMV. Cells were
cultured in the absence (-) or presence (+) of the
ligand, E2 (IO"8 M) , and dual luciferase activities were
measured 36 hr after transfection. Values (means ± SD of
a representative experiment performed in duplicate) are
plotted as a fold.
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requirements for cofactors such as TRAP220. To extend the
analysis, and given positve results in the previous
observations (Fig.4-5 and Fig.4-9), I employed cell-free
transcription assays with either TRAP/Mediator-depleted
nuclear extract or a system reconstituted with purified
factors. In the first case, depleted nuclear extracts
lacking endogenous TRAP/Mediator were complemented with
the affinity purified TRAP/Mediator complexes from
f:TRAP220AB-, f:TRAP220a-, f:TRAP220b-, and f:TRAP220abderived HeLa nuclear extracts. The inputs were normalized
on the basis of their activity to support equivalent
level of activation by GAL4-p5 3, which does not require
TRAP2 2 0 for TRAP/Mediator interaction and function. As
shown in Fig. 5-7, all the TRAP/Mediator complexes
containing each TRAP2 2 0 mutant showed modest reduction
(1.2 to 1.7 fold) in their ability to support the
activated transcription by GAL4-ER(3 LBD in comparison
with the TRAP/Mediator containing wild type TRAP220 AB.
This is very reproducible and consistent with the results
from transfection assays. In order to rule out the
possible residual TRAP220 in the depleted nuclear
extracts, I employed Namalwa nuclear extracts depleted
TRAP/Mediator by anti-TRAP220 antibody. The composition
of this assay system is essentially same as the system
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Fig. 5-7. Role for TRAP220 NR box in ER-dependent
transcription. In vitro transcription reactions contained
2 0 [iq the a-TRAP2 5 antibody-depleted nuclear extract and
17.5 ng of pA53 and 35ng of pG5A53 templates. The
transcription reactions in lanes 1-10 and lanes 11-14
additionally contained 10 ng of recombinant GAL4-ER(3 LBD
and GAL4-p53 respectively. Each purified TRAP/ Mediator
complex (f:TRAP220AB in lanes 3,4, and 11; f:TRAP220a in
lanes 5,6, and 12; f:TRAP220b in lanes 7,8, and
13;f:TRAP220ab in lanes 9,10 and 14) were added to aTRAP25 antibody-depleted nuclear extract in transcription
reactions. Relative transcription levels, determined by
phosphorimaging, are indicated.
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shown in Fig. 5-7. In this assay (Fig. 5 - 8 ) , the level of
activated transcription by GAL4-ER(3 LBD was enhanced up
to about 9 fold upon addition of TRAP/Mediator containing
TRAP220 AB (f:AB) similar to previous experiment (Fig. 45). TRAP/Mediator containing either double mutant
TRAP220ab (f:ab) or no TRAP220 (provided by Sohail Malik)
showed very modest reduction (1.5 fold) in their ability
to support GAL4-ERP LBD-activated transcription.
The discrepancy between the results from the
interaction assays and the functional assays could be due
to the following: 1) the existence of the alternative
activation pathways to support ER dependent transcription
such as other cofactors and/or 2) the lack of the
constraints which impose a requirement for TRAP/Mediator
to overcome such as chromatin blockade (see discussion).
I employed transcription assay system reconstituted with
highly purified factors because this system is so minimal
that neither activation nor negative restraints present
other than general transcription machinery. So if the
first possibility is major then I should be able to see
the difference in this sytem. The recombinant factors
expressed in and purified from bacteria included TFIIB
(one subunit [Fig. 5-9A, lanel]), TBP (lane 2), TFIIE
(two subunits [lane 3]), TFIIF (two subunits [lane 4])

155

Fig. 5-8. Role for TRAP220 in transcriptional activity of
GAL4-ER(3 LBDs in nuclear extract. In vitro transcription
reactions contained 20 \xq the a-TRAP25 antibody-depleted
nuclear extract and 17.5 ng of pA53 and 35ng of pG5A53
templates. The transcription reactions in lanes 1-4 and
lanes 5-8 additionally contained 10 ng of recombinant
GAL4-ER(3 LBD and GAL4-p53 respectively- Each purified
TRAP/ Mediator complexes (f:TRAP220AB in lanes 2 and 6;
f:TRAP220ab in lanes 3 and 7; and f:TRAP220-/- in lanes 4
and 8) were added to a-TRAP25 antibody-depleted nuclear
extract in transcription reactions. Relative
transcription levels, determined by phosphorimaging, are
indicated.
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and PC4 (1 subunit [lane 5 ] ) . The multisubunit components
purified from cell lines expressing FLAG-tagged subunits
included f: Pol II (12 subunits [lane 7]), f:TFIID (-15
subunits [lane 8]) and f:TFIIH (9 subunits [lane 9]).
Recombinant GAL4-p53 was used as an activator to
establish the functionality of this particular assay
system. As shown in Fig. 5-9B, activation (up to 19-fold)
by GAL4-p53 was achieved above the basal (activator
independent) transcription (lane 1). This indicated that
all purified factors are functional for transcription in
my highly purified transcription system, based on the
previous study showing the requirement of all the factors
for the activated transcription (Yu et al., 2001).
Consistent with the results from the nuclear extract
based assay, all the TRAP/Mediator exhibited comparable
ability to support ER dependent transcription. (Fig. 510)
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Fig. 5-9. Transcription activation by a model activator
in a cell-free system reconstituted with purified
factors. A. SDS-PAGE analysis of purified factors.
Coomassie blue R250 staining of purified general
initiation factors TFIIB, TBP, TFIIE, and TFIIF (lanes 14) and general coactivator PC4 (lane 5) were performed.
Silver staining of the immunopurified FLAG-tagged
multisubunit general initiation factors TFIID and TFIIH
and RNA polymerase II (lanes 7-9) performed. Lane 6 shows
molecular weight markers(SM). B. Activator-dependent
transcription. Transcription was conducted with the
purified components shown in panel A, GAL4-p53 and the
DNA template described previously. Fold activation above
the basal level is indicated at the bottom.
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Fig. 5-10. Role for TRAP220 NR box in transcriptional
activity of GAL4-ER|3 LBDs in nuclear extract. In vitro
transcription reactions contained purified general
transcription factors, 4EREA53 G-less reporter template
and G5A53 G-less control template as described in
Materials and Methods. Additionally, the transcription
reactions contained 10 ng of GAL4-p53 in lanes 1-5, 20 nM
of recombinant ERa in lanes 6-10 and 20 nM of recombinant
ER|3 in lanes 11-15. Each purified TRAP/ Mediator complex
(f:TRAP220AB in lanes 2,7, and 12; f:TRAP220a in lanes
3,8, and 13; f:TRAP220b in lanes 4,9, and 14;f:TRAP220ab
in lanes 5,10 and 15) were added to transcription
reactions. Relative transcription levels, determined by
phosphorimaging, are indicated.
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Chapter

6

Identification of EDD/hHYD
as an ER-interacting protein
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6.1.

Introduction

The hyd gene has originally been isolated from
Drosophila mutants showing hyperplastic discs phenotype
(Mansfield et al., 1994). The 280kDa drosophila HYD
protein shares high homology with lOOkD rat protein. This
protein was found mainly in nuclear fraction (partly in
cytosolic fraction) and expressed in all stages of
development and all tissues (although varied levels of
expression). Interestingly, this protein exhibited
decreased expression in the mutants suggesting that it is
a possible tumor suppressor.
Later, its human homologue was identified as EDD (E3
identified by differential display) by differential
display for progestin-induced gene (Callaghan et al.,
1998). In contrast to the previous implication of its
potential function as a tumor suppressor, breast cancers
showed higher expression of this gene. However, the
overexpressed proteins in cancer cells could be the
dominant negative mutants of EDD as reported in the case
of p53. EDD contains HECT (homologous to E6-AP Cterminus) domain and can bind to Ubiquitin suggesting its
function as E3 ligase in ubiquitylation. Subsequent study
showed its E3 ligase activity both in vivo and in vitro
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(Honda et a l . , 2 0 0 2 ) . Relevant to ubiquitylation,
previous studies have shown the following: 1) ER is a
ubiquitinated protein and level of ubiquitylation was
different depending on ligands (Wijayaratne and
McDonnell, 2001), 2) ER is regulated by proteasome
pathway which may somehow be involved in ER
transcriptional activity through modulation of cofactors
(Lonard et al., 2000), and 3) E6-AP is an E3 ligase and
showed coactivator activity for NR including ER (Nawaz et
al., 1999). These studies, together with the finding that
EDD/hHYD interacts with ERs, hinted at the possibility
that this protein might play a role as an ER cofactor
through its ubiquitin ligase activity. Here I describe
the very preliminary studies on this possibility.
EDD/hHYD interacts with both ERs in different manners.
Overexpression of EDD/hHYD did show very modest effect on
ER-driven transcription in transient transfection assays.

6.2. Results

6.2.1. HYD is an ER-interacting nuclear protein
To extend mass spectral analysis described in chapter
3.2, I employed western blot analysis with antibody
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Fig. 6-1. EDD/hHYD is an ER-interacting nuclear protein.
A. E2-dependent interactions of EDD/hHYD with ERa and ER(3
LBDs in nuclear extract. Immobilized GST (lane 2), GSTERaAB (lane 3), GST-ERaLBD (lanes 4 and 5), GSTER|3AB (lane 6) and GST-ER(3LBD (lanes 7 and 8) proteins
were incubated with HeLa nuclear extract in the absence
(-) or presence (+) of 1 uM E2 and bound proteins were
eluted and analyzed by SDS-PAGE and western blot with
antibody against EDD/hHYD as described in Materials and
Methods. One-tenth equivalent of the input nuclear
extract is shown in lane 1. B. E2-independent
interactions between EDD/hHYD and ERs in HeLa nuclear
extract. M2 agarose-immobilized FLAG-ERa (lanes 5 and
6) and FLAG-ER(3 (lanes 3 and 4) were incubated with HeLa
nuclear extracts in the absence (-) or presence (+) of 1
(iM E2 and bound proteins were eluted with FLAG peptide
and analyzed by SDS-PAGE and western blot with antibody
against EDD/hHYD as described in Materials and Methods.
As a control, HeLa nuclear extract proteins bound to M2
agarose alone were analyzed in lane 2. One-tenth of input
nuclear extract was analyzed in lane 1.
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against EDD for the GST-pull down assays in Fig.4-1. As
shown in Fig. 6-1A, EDD/hHYD exhibited interaction with
GST-ERa AB (lane 3) and E2-dependent interaction with
GST-ERa LBD (lane 4 versus lane 5) in the nuclear
extract. In case of ER|3, EDD/hHYD showed no detectable
interaction with GST-ER(3 AB (lane 6) and E2-enhanced
interaction with GST-ER(3 LBD (lane 7 versus lane 8) in
the nuclear extract. To examine these interactions in the
context of full-length ERs, I carried out western blot
analysis with antibody against EDD for the eluate from
the immunoaffnity pull down assay shown in Fig. 4-7. As
shown in the Fig. 6-1B. EDD/hHYD showed E2-independent
interaction with ERa (lanes 5 and 6) and ER(3 (lanes 3 and
4). Interestingly, these results indicated that EDD/hHYD
interacts with each ER in different manners (see
discussion).
The studies described above utilized nuclear extracts
as a source of EDD/hHYD, did not establish whether other
factors were essential for these interactions. To further
investigate this question, I employed the immunoaffinity
pull down assays as described in chapter 4.2. The binding
of 35S-labelled full length EDD/hHYD to purified and
immobilized full length ERa and ER(3 was analyzed. As
shown in Fig. 6-2A, full length EDD/hHYD showed the E2-
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Fig. 6-2. E2-independent direct interactions between
isolated EDD/hHYD and full-length ERs. A. Direct
interactions isolated full length EDD/hHYD and fulllength ERs. M2 agarose immobilized full length ER(3 and
ERa (lanes 2, 3, 4 and 5) and M2 agarose alone (lane 6)
were incubated with 35S-labeled (in vitro translated) full
length EDD/hHYD in the presence (+; lanes 2 and 4) or
absence (-; lanes 3 and 5) of 1 \iK E2. After washing,
bound proteins were eluted with FLAG peptide and analyzed
by autoradiography. Lane 1 shows one-twentieth of the 35Slabeled full length EDD/hHYD input. B. Direct
interactions truncated EDD/hHYD and full-length ERa. M2
agarose immobilized full length ERa (lanes 2, 3, 5 and 6)
were incubated with 35S-labeled (in vitro translated)
truncated EDD/hHYD wild type (WT HYD (S)) and mutant (MT
HYD (S))in the presence (+; lanes 2 and 5) or absence (-;
lanes 3 and 6) of 1 \xM E2. After washing, bound proteins
were eluted with FLAG peptide and analyzed by
autoradiography. Lanes 1 and 4 show one-twentieth of each
35S-labeled EDD/hHYD input.
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independent interaction with ERa, as observed with the
nuclear extract. This indicated the direct interaction of
EDD/hHYD with ERa. The interaction of the full length
EDD/hHYD with ER(3, however, was not detectable. This
might be due to the fact that the expression level of
full-length EDD/hHYD protein was so low and the
interaction of EDD/hHYD with ER(3 was weaker than with ERa
as observed in nuclear extract. Binding of truncated
EDD/hHYD (1877-2799) to immobilized ERa was analyzed
because of the following: 1) the difficulty in the
expression of full length EDD/hHYD; 2) the truncated
EDD/hHYD (1877-2799) contains a LXXLL motif among five
LXXLL motifs (at amino acids 248, 1102, 1255, 1398, and
2428); and 3) the availability of the construct encoding
the truncated EDD/hHYD (1877-2799). As shown in Fig. 6-2B
this truncated EDD/hHYD showed E2-independent interaction
with ERa (lanes 2 and 3) as observed with the full-length
EDD/hHYD. This result confirms that the isolated EDD/hHYD
can directly interact with ERa.
To examine the role of the ubiquitin binding
activity in the interaction of EDD/hHYD, binding of a
mutant EDD/hHYD (1877-2799, C2768A) to immobilized ERa
was analyzed. This mutant EDD/hHYD also showed E2independent interaction with ERa (lanes 5 and 6) as
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observed with the corresponding wild-type fragment. This
indicated that the ubiquitin binding activity of EDD/hHYD
is not required for the direct interaction between the
isolated fragment of EDD/hHYD and ERa.

6.1.2. Effect of HYD on ER-mediated transcription
To examine role of EDD/hHYD in ER-mediated
transcripton, I employed transient transfection assays.
CV1 cell line is a simian kidney cell line which does not
express ER and used commonly for the transient
transfection assays with ER. CV1 cells were transfected
with the indicated amounts of the plamids harboring ERa
and EDD/hHYD, in combination with a reporter plasmid
containing three ERE and core promoter, in the presence
(E2) or the absence of E2 (No E2).
In this assay (Fig. 6-3), a strong E2 response (up to 30fold induction at the 1 ng of ERa) was observed and this
was further enhanced upon simultaneous transfection of
the plasmids encoding full length EDD/hHYD. Due to the
repressive effect by EDD/hHYD (1.4-fold at the
concentration of 125 ng and 2.7-fold at the concentration
of 250 ng of plasmids for EDD/hHYD) the net induction of
E2 response was enhanced up to 6-fold by EDD/hHYD. This
result was very reproducible, however, it was not
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Fig. 6-3. Role of EDD/hHYD in ERa-dependent transcription
in CVl cells. CVl cells were transfected with indicated
amounts of expression vectors for ERa and EDD/hHYD in
combinations with 3ERE-luciferase reporter and control
luciferase pRL-CMV as described in Materials and Methods.
Cells were cultured in the absence (-) or presence (+) of
the ligand, E2 (IO"8 M) , and dual luciferase activities
were measured 36 hr after transfection. Values (means ±
SD of a representative experiment performed in duplicate)
are plotted as a fold.
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possible to confirm the expression of exogenous EDD/hHYD
probably due to the limited sensitivity of the antibody
against EDD/hHYD. Considering the observation of E2independent interaction of EDD/hHYD with ERa, this
indicated that EDD/hHYD could be a potential cofactor for
ERa through its dual role by acting as a corepressor in
the absence of E2 and as a coactivator in the presence of
E2.
To extend this analysis with more physiologically
relevant conditions, an Ishikawa cell line was employed.
Ishikawa cells were transfected with indicated amounts of
plasmids encoding full length EDD/hHYD in combinations
with each reporter plasmid containing three ERE sites
(Fig. 6-4A) or an AP-1 site (Fig. 6-4B) or core promoter
only (Fig. 6-4C).
As shown in Fig. 6-4A, a very strong E2 response (up
to 100-fold) by endogenous ERs was observed with a
synthetic reporter containing three ERE sites. In
contrast to what was observed with CVl cells, E2 response
was moderately enhanced (1.5 fold) at the lowest
concentration (10 ng of plasmid) of EDD/hHYD and then
attenuated (up to 1.5 fold) upon increasing concentration
of EDD/hHYD essentially in a dose dependent manner
although the level of ER-mediated transcription was not
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Fig. 6-4. Role of EDD/hHYD in ER dependent transcription
in Ishikawa cells. Ishikawa cells were transfected with
indicated amounts of expression vectors for EDD/hHYD in
combinations with luciferase reporter containing 3ERE
(A), AP-1 (B) and no activator binding site (C) and
control luciferase pRL-CMV as described in Materials and
Methods. Cells were cultured in the absence (-) or
presence ( + ) of the ligand, E2 (IO"8 M) , and dual
luciferase activities were measured 36 hr after
transfection. Values (means ± SD of a representative
experiment performed in duplicate) are plotted as a fold.
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affected by EDD/hHYD in the absence of ligand or in the
presence of tamoxifen. This modest effect by exogenous
EDD/hHYD might be due to the effect by endogenous
EDD/hHYD in Ishikawa cells and the artificial effect by
the multiple sites of ERE which might bypass the
requirement for cofactors.
A reporter containing one AP-1 site was employed to
address the second possibility as well as to examine
promoter specificity of the role of EDD/hHYD, if any. As
shown in Fig. 6-2B, a weaker E2 response (up to 7-fold)
from the AP-1 site than from three ERE sites was
observed. As described previously, Ishikawa cells
exhibited a strong tamoxifen response (up to 7-fold) from
the AP-1 site. Although the absolute level of
transcription activity from AP-1 site in the presence of
either E2 or tamoxifen appeared to be attenuated by 4fold at the highest concentration of EDD/hHYD the net
induction was not affected by EDD/hHYD due to the
attenuation of the transcription activity from AP-1 site
in the absence of ligand. The basal activity from a
control reporter containing only core promoter (Fig. 64C) was not affected at the highest concentration of
EDD/hHYD in the presence or the absence of E2. This
indicated that the reduction in the level of activity
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from the AP-1 site could be mainly due to the reduction
in the activated-transcription not the basal (activatorindependent) activity.
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7

ER mediates estrogen signaling through regulation of gene
expression via direct and/or indirect ways by a variety
of mechanisms as described above. Considering the broad
functions of estrogen, the existence of only two ERs may
require such diversity and complexity of ER action
mechanisms. Cofactors are considered as ultimate
integrators and processors of these various mechanisms.
The diversity of cofactors provides (1) the interfaces to
accommodate various regulatory information imparted by
enhanceosomes, chromatin structure, and general
transcription machinery; (2) the means to integrate
secondary signaling pathways with estrogen signaling via
cross-talk; and (3) mechanisms, through cofactor
modulation, to dictate the specificity of ER function
depending on the different cell types, promoters and
ligands. Therefore, understanding the cofactors that
regulate ER function is particularly interesting, and
important.
With respect to this notion, I initially proposed
the existence of more novel cofactors involved in ER
function, on the basis of the existence of receptor
subtypes (a and (3) with different tissue distributions,
functions and ligand responses; cell and promoter
context-dependent functions of resident (AF-1 and AF-2)
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activation domains; and the existence of selective
estrogen receptor modulators (reviewed in McDonnell,
1999).
The object of this thesis work was to identify the
ER-interacting proteins (presumptive cofactors) that are
involved in specificity of subtypes of ER and/or cell
types. Here I described the purification and partial
characterization of ER LBD-interacting proteins in an E2dependent manner.

7.1. Cell type specificity of ER-interacting proteins

The apparent lack of major differences in the
electrophorectic migration patterns of the polypeptides
interacting with GST-ERa LBD and GST-ER(3 full-length in
the cell types that I used was quite surprising. However,
cell type specific functions of ERs might be mediated
through proteins that weakly interact with ER LBDs and/or
a repertoire of cell type-specific proteins that interact
with the AF-1 domains of ERs although I have not pursued
in sufficient depth to ascertain. Therefore, the initial
hypothesis could be still valid. In support of this idea,
the recent study showed the difference in the expression
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level of SRC-1 between MCF-7 and Ishikawa cells
contributes the difference in cell type-specific ER
function in these cell lines (Shang et al., 2000).

7.2. Subtype Specificity of ER functions

Although previous studies have reported activation
by ERa in cell free systems (Kraus and Kadonaga, 1998; Wu
et al., 1999), this is the first report to compare the
intrinsic activities of ERa and ER(3 in a fully-defined
system reconstituted with essentially homogeneous
factors. Our observation that ER(3 is more potent than ERa
in the TRAP/Mediator-dependent assay system is somewhat
surprising in view of reports that ERa is generally more
active than ER(3 in transfection assays with ectopic
reporters (reviewed in Hall and McDonnell, 1999; Nilsson
et al., 2001; Pettersson and Gustafsson, 2001).
However, the in vitro transcription data correlate
directly with my observation that intact ER(3 has a higher
affinity for TRAP/Mediator than does intact ERa.
Furthermore, promoter and cell context-dependent effects
of ER AF-1 and AF-2 domain are well established (reviewed
in Hall and McDonnell, 1999; Nilsson et al., 2001;
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Pettersson and Gustafsson, 2 0 0 1 ) . Especially relevant to
the present findings, an ER(3 lacking the AB domain is
much more active than an ERa lacking the AB domain in
certain (e.g. HeLa) cell types (Hall and McDonnell,
1999). This reflects the well established synergy of
ERa AF-1 and AF-2 domains (Hall and McDonnell, 1999;
Nilsson et al., 2001; Pettersson and Gustafsson, 2001)
and an apparent inhibitory effect of ER(3 AF-1 on ER(3 AF-2
function (Hall and McDonnell, 1999). Since ERa AF-1
function has been shown to involve site-specific
phosphorylation and recruitment of cofactors not present
in our in vitro assay (Watanabe et al., 2001 and
references therein) my results likely reflect an
intrinsic AF-2 function mediated through TRAP/Mediator
interactions.
In contrast to this thesis study, but consistent
with the cell-based studies, a recent report showed that
ERa is more potent than ER(3 in an in vitro transcription
assay with chromatin template but not with a naked DNA
template (Cheung et al., 2003). Cheung et al also
demonstrated that A/B region of ERa but not ER(3 contained
potent transcriptional activity with chromatin template
based assays not with naked DNA based assays (Cheung et
al., 2003). Thus, it was suggested that the stronger
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activity of ERa than that of ER|3 shown in their study
could be mainly due to the stronger AF-1 activity of ERa
than that of ER(3 (Cheung et al. , 2003). Considering the
fact that Cheung et al employed the extract-based systems
for both chromatin assembly and transcription assays, the
difference in the transcriptional activity of ERa and ER(3
observed in their study could be significantly mediated
via additional factors, which present in the extract that
support ERa AF-1 activity at the step of antirepression
of the chromatin, rather than the intrinsic
transcriptional attributes (ER(3>ERa) mediated via GTFs
(TFIIB, TFIID, TFIIE, TFIIH, polll, and PC4) and
TRAP/Mediator as seen in this thesis study. Also of
importance is my observation that the differential
affinities of TRAP/Mediator for intact ERs (|3>a) are
reversed when the AB domains are absent (a>(3). This
clearly indicates an ability of the AB domains to
modulate interactions of the LBD (AF-2) domains with
TRAP/Mediator (and probably other cofactors), although it
is not clear whether this reflects an inhibitory effect
of the ERa AB domain on ERa AF-2 interactions and/or a
stimulatory effect of the ER(3 AB domain on ER(3 AF-2
interactions with TRAP/Mediator. A very recent report on
an inhibitory activity of part of the ERa AB domain
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strongly supports the first possibility

(Metivier et al.,

2002). Additionally, the results reported here likely
reflect intrinsic (intramolecular) effects of the AB
domain(s), rather than effects of additional AB domaininteracting factors, since similar effects were observed
with unpurified (nuclear extract) and highly purified
TRAP/Mediator. Although both Freedman and colleagues
(Burakov et al., 2000) as well as I failed to see
differential interactions of ERa and ER(3 with isolated
TRAP220, Treuter and colleagues (Warnmark et al., 2001)
have reported stronger interactions of isolated TRAP220
(and TRAP22 0 fragments) with ER(3 than with ERa. Although
the basis for these discrepancies is not clear, the
latter results are consistent with our observation of
stronger ER(3 interactions with TRAP2 2 0 in the more
physiological context of the functional TRAP/Mediator
complex. Given that other AF-2-interacting coactivators
such as pl60/SRC members show little subtype selectivity
in ER binding (Burakov et al., 2000; Warnmark et al.,
2001) and as discussed by Warnmark et al. (Warnmark et
al., 2001), the differential binding of TRAP/Mediator to
ERa and ER(3 has significant implications for differential
functions of these receptors in diverse tissues that
could show modulations of TRAP/Mediator components. The
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differential recruitment of these factors may also
contribute to the tissue-selective action of selective ER
modulators. Finally, apart from a number of other
interacting factors (reviewed in Nilsson et al., 2001)
implicated in ER functions, it will be important to
further characterize the additional ER-interacting
polypeptides identified here (Fig. 3-2) for possible
subtype-specific functions and interactions with
TRAP/Mediator, other cofactors, and the general
transcription machinery.

7.3. TRAP/Mediator is a Bona Fide Estrogen Receptor
Coactivator

Following earlier reports of ligand-dependent
interactions of ERs with the isolated TRAP220 subunit of
the multicomponent (circa 25 subunit) TRAP/Mediator
complex (Burakov et al., 2 000; Warnmark et al., 2 001;
Yuan et al., 1998; Zhu et al., 1999), this thesis study
provides concrete evidence for direct TRAP2 2 0- and
ligand-dependent interactions of ERs with the intact
TRAP/Mediator complex and a direct role for the complex
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in ER function through the general transcription
machinery.
While a role for the complete TRAP/Mediator in ER
function had been inferred from TRAP220 binding studies
(Burakov et al., 2000; Warnmark et al., 2 001; Yuan et
al., 1998; Zhu et al., 1999), and from the precedents
established with TR and VDR (Fondell et al., 1996; Rachez
et al., 1998), the concurrent failures (see above) to
show any interactions of the intact TRAP/Mediator complex
with ERs had led others to speculate that class I
(steroid hormone) nuclear receptors might utilize
different cofactors from TRAP/Mediator (Burakov et al.,
2000). This thesis work provides the first evidence for
the involvement of the intact TRAP/Mediator complex in
the function of class I (steroid hormone) nuclear
receptors.
Consistent with the earlier results, and with
structural conservation of the AF-2 domain implicated in
ligand-dependent interactions of many cofactors, this
thesis work shows ligand-dependent interactions of
TRAP/Mediator both in nuclear extracts and in purified
form with both ERa and ER(3 LBDs. The latter results
establish that these interactions are direct, while
analyses with extracts from TRAP220"/_ fibroblasts
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establish an essential role for TRAP220 in these
interactions. Consistent with their role in TR and VDR
interactions, the TRAP220 LXXLL motifs (most notably NR
box 1) have been implicated in ligand-dependent ERa and
ER|3 interactions with isolated TRAP220 (Burakov et al.,
2000; Warnmark et al., 2001). Thus, although reported
ligand-independent interactions of ERs with other
isolated TRAPs (Burakov et al., 2000) could be relevant,
they are insufficient for demonstrable interactions of
the entire TRAP complex with ERs. Related, I did not
observe any direct interactions of TRAP/Mediator with ER
N-terminal AB domains.
Importantly, the physiological relevance of the in
vitro interactions is substantiated by our demonstration
of an in vivo association of the entire TRAP/Mediator
complex with an ERa derivative lacking the AB domain.
Along with the in vitro data, this observation makes
improbable the suggestion (Burakov et al., 2000) that
TRAP22 0 may mediate ER function independently of many or
all of the other TRAP/Mediator subunits. In a further
analysis of the significance of TRAP/Mediator
interactions, and perhaps most importantly, this thesis
work demonstrates that the purified TRAP/Mediator complex
markedly enhances ER function on DNA templates both in
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nuclear extracts and in a system reconstituted with
highly purified factors. This firmly establishes a direct
function for TRAP/Mediator in mediating the action of ERs
on target promoters in conjunction with the general
transcription machinery.
A recent report utilizing in vitro transcription
assays with a chromatin template showed only a modest
effect (1.3 to 2 fold on activated transcription by ERa)
on ER-dependent transcription upon TRAP/Mediator
depletion (Acevedo and Kraus, 2003). This result is
contrast to my results, which showed the significant
effect (4 to 7 fold) by TRAP/Mediator on the activated
transcription by ERs or GAL4-ER LBDs. The difference
between my study and the study by Acevedo and Kraus might
be due to different depletion procedures such as using
different antibodies. Another possibility for the
different results between my study and their study could
be difference in templates (naked DNA in my study versus
chromatin template in their study) although this is quite
unlikely considering an earlier study showing the
significant effect on HNF-4 dependent transcription upon
TRAP/Mediator depletion in nuclear extract-based in vitro
transcription assays with both DNA and chromatin
templates (Malik et al., 2002). Most of all, the
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interpretation of the study by Acevedo and Kraus is
difficult due to the the lack of restoration experiment
by adding exogenous TRAP/Mediator complex and possible
complement by Drosophila Mediator existing in S-190
extracts.

7.4. TRAP220 is an essential anchor for ER-TRAP/Mediator
interaction

Although a number of previous studies suggested the
potential involvement of the TRAP220 subunit in ER
function (Burakov et al., 2000; Warnmark et al., 2001;
Shang et al., 2000; Zhu et al., 1999; Yuan et al., 1998),
these studies employed only isolated TRAP220 or fragment
of TRAP220. Thus, these studies were not able to score
the function of TRAP220 in the context of intact
TRAP/Mediator. To address this issue, TRAP220-/- MEFs
were utilized to examine the roles for TRAP220 in the
interaction and function of TRAP/Mediator in ER-driven
transcription. This study was based on the previous
observation that the residual Mediator subunits can form
a functional complex for certain activators such as GAL4VP16 (unpublished observation by Chao-Xing Yuan). As
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mentioned above, the loss of TRAP220 abolished the ERTRAP/Mediator interaction in nuclear extract indicating a
role for TRAP220 as an essential anchor for the strong
TRAP/Mediator-ER interaction. However, and surprisingly,
transient transfection assays with TRAP220-/- MEFs
revealed that ER-driven transactivation was reduced only
modestly (2 fold) by deletion of TRAP220, in contrast to
what was observed with TR. This was unexpected
considering the significant effect on ER-TRAP/Mediator
interaction by deletion of TRAP220. This discrepancy
might be due to the existence of redundant mechanisms
that likely compensate for potential defects in ER
function by the loss of TRAP220 in MEFs. This could be 1)
the presence of redundant cofactors that play similar
roles as TRAP220 in MEFs and/or 2) the absence of natural
constraints (such as a natural chromatin structure) that
particularly impose a requirement for TRAP22 0 to overcome
and/or 3) physiologically irrelevant cellular environment
for ER function given that MEFs do not express ERs and/or
4) non-physiological template containing multiple ERE
sites.
A consideration of studies with PPARy, another
receptor that shows ligand-dependent interaction with
TRAP220, exemplified this point. Thus, transient
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transfection assays with MEFs failed to show a
significant defect in PPARy-driven transcription in the
absence of TRAP220 (unpublished observation by Chao-Xing
Yuan), however, adipogenesis differentiation assay
revealed the absolute requirement of TRAP220 for PPARyinduced adipogenesis differentiation and for endogenous
PPARy target gene expression (Ge et al., 2002). Moreover,
the GST pull-down assays with TRAP220-/- nuclear extracts
showed that TRAP220 is an essential for strong
interactions of PPARywith the TRAP/Mediator, as observed
for ER. These results strongly support the above
possibilities and necessitate more physiological cellbased assays that employ cells in where ER normally
function in the expression of natural target genes.
Based on previous studies in assaying the function
of TRAP/Mediator in ER dependent transcription, I
employed cell-free assays, as an alternative approaches,
to assess the role of TRAP220 in ER-dependent
transcription, particularly in the context of intact
TRAP/Mediator. However, TRAP/Mediator complex lacking
TRAP2 2 0 showed no defect in ER-dependent transcription in
this particular assay- This unexpected observation,
together with the observation of the requirement of
TRAP220 for the ER-TRAP/Mediator interaction, led to the
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speculation that 1) whereas TRAP220 play a pivotal role
in mediating ER-TRAP/Mediator interaction, this may not
be essential for TRAP/Mediator to support ER dependent
transcription at the naked DNA template in vitro and 2)
factors other than ER may be able to recruit
TRAP/Mediator lacking TRAP220 to the promoter through
other subunits under the ambient conditions in cell-free
transcription assays. The dispensability of TRAP220 for
TRAP/Mediator function in activated transcription in
cell-free transcription assays has been suggested by
previous studies in cell free systems showing 1) that
TRAP/Mediator lacking TRAP220 can support activated
transcription by certain activators such as GAL4-VP16 and
HNF-4 (unpublished observation by Sohail Malik) and 2)
that a preparation of PC2 containing no detectable levels
of TRAP240, 230, 220, can support activated transcription
by GAL4-VP16, GAL4-AH and HNF-4 as well as intact
TRAP/Mediator (Malik et al., 2000). Moreover, and
importantly, The possibile existence of other factors
(not activator) that can recruit the residual (TRAP220deficient) TRAP/Mediator to the promoter through other
subunits of TRAP/Mediator was indirectly suggested by the
previous studies showing an obligate role of the
TRAP/Mediator in supporting basal (activator-independent)
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transcription in depleted extracts (Baek et a l . , 2002;
Mittler et al., 2001). More direct evidence for this was
provided by a subsequent study showing that TRAP/Mediator
was recruited to the promoter in the absence of the
activator HNF-4 (Malik et al., 2002).
In addition to the basal effect, TRAP/Mediator also
supports ER-activated transcription. The question then
arises as to how TRAP/Mediator supports ER-activated
transcription. One possible answer to this question is
that although ER might not be able to directly recruit
TRAP/Mediator due to lack of TRAP220, residual
TRAP/Mediator lacking TRAP220 could function in ERactivated transcription via indirect recruitment through
other factors.
Thus, the failure to show a role of TRAP220 in the
function of TRAP/Mediator to support ER-dependent
transcription using cell-free assays might be due to an
intrinsic limitation of cell-free assays. Therefore, it
will be important to develop assays that impose more
physiological conditions before taking the conclusions
regaring the roles for TRAP220 in the function of
TRAP/Mediator to support ER-dependent transcription.
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7.5. Role for TRAP220 NR boxes

The LXXLL motif was first identified as a signature
sequence motif, in other nuclear receptor coactivators,
that is necessary and sufficient for direct interactions
with NRs (Heery et al., 1997). This motif has been found
in most NR cofactors (Heery et al., 1997). Furthermore,
this motif functions as a specificity determinant for
interactions between NRs and cofactors (Mclnerney et al.,
1998). For example, consistent with this notion, it was
indicated by others that the second (C-terminal) LXXLL
motif (NR box2) of TRAP2 2 0/DRIP2 05 showed the interaction
with TR (Yuan et al., 1998) and VDR (Rachez et al.,
1998), whereas the the first motif (more N-terminal)
LXXLL motif (NR boxl) showed a preferred interaction with
ERs (Burakov et al., 2 000; Warnmark et al., 2 001).
However, in contrast to these previous reports, this
thesis study revealed that ER LBDs prefer TRAP220 NR box2
to NR boxl in the isolated TRAP220 AB. The difference may
be due to the different assay condition. Interestingly,
full-length ER(3 did not show any preference in the
context of intact TRAP/Mediator and both NR boxes were
found to be necessary and sufficient for strong ERTRAP/Mediator interaction. This, together with previous
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reports, indicated that each NR box is sufficient for ERTRAP220 interaction but not sufficient for efficient ERTRAP/Mediator interaction. This suggested cooperative
action of two NR boxes in ER-TRAP/Mediator interaction.
In consistent with these results, transient
transfection assays with MEFs revealed that exogenous
expression of full-length TRAP220 harboring mutations in
either or both NR boxes failed to restore the defect in
ER-driven transcription. The cell-free assays both with
crude nuclear extract and with purified factors showed
that TRAP/Mediator complex containing TRAP2 2 0AB NR
mutants exhibited only very modest defects (1.5 to 2
fold) in ER-dependent transcription. This is quite
surprising, considering previous observation of more
significant effects of the same TRAP220AB NR mutants on
the activated-transcription by other nuclear receptors
such as TR (unpublished observation by Sohail Malik and
Mohamed Guermah) or PPARy (unpublished observation by
Mohamed Guermah) in cell-free transcription assays.
These modest effects of TRAP/Mediator containing
TRAP220AB NR mutants could be due to the same reasons for
the results of many analyses with TRAP/Mediator lacking
TRAP220, as addressed in the previous section (chapter 64), provided that mutations of either or both NR boxes of
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TRAP220 are functionally equivalent to complete loss of
TRAP220. However, and more importantly, this functional
outcome could be due to the residual interactions between
ER and TRAP/Mediator containing TRAP2 2 0AB harboring
mutations in either or both NR boxes. These weak but
significant interactions of TRAP/Mediator containing
TRAP22 0AB NR mutants with ERs could be enough for
function. In support of this idea, the TRAP220 NR boxes
are dispensible for the physiological function of PPARy
which absolutely requires TRAP220 (unpublished
observation of Kai Ge).

7.6. Identification of EDD/hHYD as an ER-interacting
protein

The previous studies on the EDD/hHYD summarized in
the chapter 6, pointed out strong relevane of EDD/hHYD in
ER function. This thesis work provided evident to support
this possibility although the data presented here is yet
preliminaryEDD/hHYD interacts with each ER in subtype-dependent
manners. EDD/hHYD interacts with GST-ERa AB but not with
GST-ER(3 AB. This suggested the possible role of EDD/hHYD
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in the AF-1 activity of ERa.

The isolated ERa LBD showed

E2-dependent interaction with EDD/hHYD, whereas the
isolated ER|3 LBD showed E2-enhanced interaction. The
reason for the less E2-dependency of the interaction of
EDD/hHYD with ER(3 LBD than with ERa LBD has yet to be
known. It could be due to potential involvement of other
factors in nuclear extract in the interaction of EDD/hHYD
with each ER LBD and/or intrinsic properties of ER LBDs
such as structural difference of each ER LBD. Although it
needs to be established the difference in E2-dependency
of the interaction between EDD/hHYD and each ER LBD
suggested the potential involvement of EDD/hHYD in the
subtype-specific response of ER to different ligands. In
contrast to what was observed with TRAP/Mediator,
EDD/hHYD interacts with full length ERa much stronger
than with full length ERp, as observed with ER LBDs
although to somewhat lesser extent. The reason for the
stronger interaction of EDD/hHYD with full length ERa
compared to full length ER(3 has yet to be known. However,
it appeared to be same with the isolated EDD/hHYD this
might reflect the intrinsic difference in ERa and ER(3
rather than the other factors in the nuclear extract.
Interestingly, EDD/hHYD interacts with full length
ERs in E2-independent manners. The reason for the loss of

199

E2-dependency has yet to be known, however, these resuts
indicated the modulatory effect of AB regions of ERs, via
the intrinsic properties of AB regions of ERs, on the
interaction of EDD/hHYD with corresponding LBDs, as
suggested from the studies with TRAP/Mediator.
To examine the potential role of EDD/hHYD as a
cofactor for ERs, the transient transfection assays with
two different cell types were carried out. In CVl cells,
the transfection of exogenous EDD/hHYD resulted in the
apparent net induction of ERa-mediated transcription
through its dual action by stimulating E2-dependent
activity of ER and repressing E2-independent activity. In
contrast to this, Ishikawa cells exhibited the reduction
in the activity from the multiple ERE sites as well as
single AP-1 site upon the transfection of exogenous
EDD/hHYD in a ligand-independent manner. The discrepancy
in the results with two cell lines could be due to the
intrinsic properties of these cell lines, particularly
the level of endogenous EDD/hHYD protein as well as ERs.
For example, if Ishikawa cells overexpress endogenous
EDD/hHYD one might not be able to see the effect of
exogenous protein. A report that was published during
this thesis work provided evidence that EDD functions as
a coactivator for PR and VDR but not for ER (Henderson et
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a l . , 2 0 0 2 ) . Henderson et al also reported that neither
the ubiquitin binding domain nor the E3 ligase activity
was required for such cofactor function (Henderson et
al., 2002).

7.7. Identification of ERLBD-interacting proteins
independent of TRAP/Mediator

As detailed in Fig. 3-3, circa 12 polypeptides were
identified as ERLBD-interacting proteins (ERLIPs).
Although the functional relevance of their interactions
with ERa LBD remains to be established there is some
evidence suggesting their potential involvement in ER
functions.

1) DNA-dependent Protein Kinase (DNA-PK)
The largest protein among the ERLIPs was identified
as the 450 kDa DNA-PK catalytic subunit. The possible
role for this protein in modulation of ER function was
first suggested by an early report showing its ability to
phosphorylate ERa in vitro (Arnold et al., 1995).
Additional evidence for the potential link between DNA-PK
and NR function came from the studies showing an

201

interaction of DNA-PK with certain cofactors such as TRBP
and GCN5 (Ko et al., 2000). TRBP interacts with CBP/p300
and DRIP130/hSUR2, a component of the TRAP/Mediator and
activates transcription by TR and ER (Ko et al., 2000).
This study also demonstrated DNA-independent
phosphorylation of TRBP by DNA-PK, although its
functional relevance was not shown (Ko et al., 2000).
Furhtermore, phosphorylation of GCN5 by DNA-PK was found
to down regulate the HAT activity of GCN5, resulting in
an inhibitory effect on transcription.
Based on these results, one can propose two possible
mechanisms by which DNA-PK modulate ER functions: 1)
direct roles for DNA-PK in modulation of ER activity
through its phosphorylation of ERa and 2) the indirect
roles via interactions with other cofactors by
facilitating recruitment and/or modulating cofactor
activity through its kinase activity.

2) Transformation/transcription domain-associated
protein (TRRAP)
The second largest protein in ERLIPs was identified as
the TRRAP component of GCN5/PCAF complexes (Vassilev et
al., 1998). This is consistent with the previously
documented E2-dependent recruitment of PCAF to ER-
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regulated target genes (Shang et al., 2 0 0 0 ) .
Additionally, there is a report suggesting the
involvement of TFTC, one of GCN5/PCAF complexes, in ERa
dependent transcription through direct interaction of
TRRAP with ERa (Yanagisawa et al., 2002). This study also
provided evidence that TRRAP is involved in E2-dependent
cell growth of breast cancer cells. However, the data
from in vitro transcription assays were not so convincing
because this study failed to demonstrate the activity by
TFTC complex by itself and the effect on cell growth by
antisense TRRAP could be a secondary effect.

3) RNA Polymerase II subunit
Although the direct interaction of RNA pol II with ER
has not been indicated heretofore, RNA pol II has been
shown to be associated with TRAP/Mediator in certain
cases. Therefore, it is highly possible that RPB2 might
indirectly interact with ER LBD via TRAP/Mediator.

4) Striatin, S/G2 Nuclear autoantigen (SG2NA), Zinedin,
Protein phosphatase 2A (PP2A) and hMOBl/Phoecin
These proteins were shown to form a PP2A holoenzyme
complex with calcium-independent, okadaic acid-sensitive
phosphatase activity (Baillat et al., 2001; Moreno et
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a l . , 2001; Moreno et al., 2 0 0 0 ) . These studies suggested
that Striatin, S/G2 Nuclear autoantigen (SG2NA), Zinedin,
and hMOBl/Phoecin form a novel B subunit of PP2A
holoenzyme.
PP2A is a heterotrimeric serine/threonine phosphatase
consisting of structural (A) subunit, catalytic(C)
subunit and regulatory (B) subunit. Existence of several
types of B subunits-B, B', B", B'" could produce many
different holoenzyme assemblies which can modify specific
substrates in distinct cellular environment. This
structural diversity and complexity of PP2A could create
the multifunctional nature of PP2A that is involved in
cellular metabolism, neuronal signaling, development,
cell cycle regulation and viral transformation.
Striatin, SG2NA and Zinedin have been shown to be a
striatin family due to their high homology. These
proteins contain multiple protein-protein interacting
domains including a caveolin-binding domain, potential
coiled-coil structure, a calmodulin-binding domain, a
membrane-binding domain and a WD-repeat domain (Castets
et al., 2000). With respect to these structural features
these proteins have been thought to function as
scaffolding proteins by assembling a large number of
proteins into a complex (Castets et al., 2000). Thus,
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these proteins target other proteins to certain cellular
compartments. Additionally, their binding ability to
calmodulin in the presence of calcium suggesting their
function in or depending on calcium signaling (Bartoli et
al., 1998) (Castets et al., 2000). Another interesting
feature of these proteins is that they expressed
primarily in the central nervous system suggesting their
function in the brain.
Among those, SG2NA was originally isolated as an
autoantigen in a human cancer patient (Muro et al., 1995)
and localized to the nucleus although it is primarily
localized to the cytosol and the membrane. As its name
indicated its expression peaks during the S and G2
suggesting its involvement in cell cycle (Muro et al.,
1995) .
Striatin was found in neurons of mammalian basal
ganglia and cranial and spinal motor nuclei specifically,
neuronal dendrites (Castets et al., 1996; Moqrich et al.,
1998; Salin et al., 1998). Different from SG2NA, striatin
was found in the cytosol and in membranes (Castets et
al., 1996) and contains two polybasic domains that are
absent in SG2NA and may facilitate association with the
post-synaptic membrane (Castets et al., 1996). Its
physiological function was further supported by the
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observation that downregulation of striatin in vivo using
antisense oligonucleotides decreased locomotor activity
and reduced growth of dendrites in vitro (Bartoli et al.,
1999). These results suggested that striatin with the
PP2A A/C heterodimer target to a cellular
microenvironment in which it may play a role in the
modulation of calcium-dependent neuronal signaling and
possibly remodeling of the cytoskeleton.
There are a couple of reports suggesting the
involvement of these proteins in regulation of
transcription. An early report provided evidence that
PP2A catalytic subunit can potentiate transcription from
the AP-1 sites (Alberts et al., 1993). SG2NA was
suggested to contain transcriptional activity (Zhu et
al., 2001). Although their involvement in estrogen
signaling has not yet been clearly demonstrated there is
a report showing that direct interaction of PP2A
catalytic subunit with ERa and increase in ER-driven
transcription upon treatment of okadaic acid via inducing
ER-MAPK interaction (Lu et al., 2003). However, it is
more likely that PP2A might involve in ER-driven
transactivation rather than inhibition based on the
observation of the ligand-dependent interaction of PP2A
with ERa. Moreover, the interpretation of the data on ER-
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driven transactivation with okadaic acid is difficult
based on the following: 1) the effect of okadaic acid
could be secondary effect and 2) one should include
proper control for the specificity such as by showing
that other activator dependent transcription is not
affected.

5) Calmodulin-dependent kinase II (CaMKII)
CaMKII, similar to CaMKI, is widely expressed
throughout the body whereas CaMKIV is relatively
restricted to the brain, T-lymphocytes and post-meiotic
male germ cells. Its dual roles in transcription
regulation have been suggested by a report showing that
CaMKII phosphorylates ATF-1 at Ser63 and activate its
transcriptional activity by enhancing the interaction
with CBP while it phosphorylates CREB at Serl42 and
inhibit its transcriptional activity by reversing the
activation of CREB by destabilizing the association
between CREB and CBP (Shimomura et al., 1996). Similar
to PP2A this kinase may be more relevant to the
nongenomic actions of ER rather than genomic actions.
However, this possibility remains to be investigated.
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7.8.

Perspectives

Estrogen involves diverse physiological processes in
various tissues. Thus, natural estrogen withdrawl in
women in the postmenopausal period has caused
pathological symptoms called postmenopausal syndrome.
Particularly, today the increasing life span has
generated increasing population of women in the
postmenopause stage and longer postmenopausal period of
their lives meaning that more women would suffer from
postmenopausal syndrome for longer period. Estrogen also
has known to be involved in the carcinogenesis of breast
and uterine. Therefore, estrogen has been getting
considerable clinical and pharmaceutical attention due to
its significance in women's health. In particular, it is
of great interest to develop new SERMs as substituents
for hormone replacement therapy that retain the
beneficial effects of estrogen, but lack of higher risk
of breast cancer or uterine cancer. Understanding the
molecular mechanism of estrogen action and its receptor
ER can eventually be foundation for the discovery of
proper SERMs to treat or prevent estrogen-related
diseases.
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A prerequisite for understanding the molecular
events underlying the ER-mediated estrogen action is the
identification of all the players involved. In this
respect I believe that my thesis work has contributed to
scientific progress by identifying and partially
characterizing some of the ER-interacting proteins
(presumptive cofactors).
Future studies must elucidate the physiological
roles for TRAP/Mediator in ER function. As reviewed in
the previous sections, TRAP/Mediator would link the
diverse gene-specific transcriptional factors and basal
transcription machinery and provides accommodating
surfaces to transcription apparatus with its modular and
dynamic organization upon diverse regulatory signals. In
this way, TRAP/Mediator could act ultimately (1) to
assemble various regulatory signals from enhanceosomes
into an integrated synergistic response to the basal
transcription machinery at the promoter of a given gene
and (2) to coordinate afferent signals from various
signaling pathways in the context of the cellular
environment into an incorporated differential response to
the cell and tissue of a whole organism. In view of the
first aspect, future studies must be directed towards
illumination of the molecular mechanisms by which
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TRAP/Mediator connects ERs and the components of basal
transcription machinery- In view of the second aspect, it
will be very important and interesting to study the
involvement of TRAP/Mediator in various signaling
pathways involved in differentiation and/or development.
In other words, the physiological relevance of
TRAP/Mediator in ER function, as observed in PPARyinduced adipocyte differentiation should be investigated.
For example, RNAi with breast cancer cells to see
potential relevance of amplification of TRAP220 in breast
cancer. Generation of tissu-specific conditional TRAP220
knock-out mice would provide more insights of the role of
TRAP22 0 and TRAP/Mediator complex in the mammalian
physiology including nuclear receptor function.
Furthermore, such physiological approaches could assess
the functional relevance of absolute requirement of
TRAP2 2 0 in ER-TRAP/Mediator interaction.
Other future studies will have to characterize the
function of ER-interacting proteins other than
TRAP/Mediator in both nongenomic and genomic actions of
ERs, elucidate the molecular mechanism leading to ER
function through these proteins, and address questions of
possible subtype specificities of these proteins.
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Another question provoked by the existence of
diverse cofactors for ER function is the functional
relationship among these proteins whether they function
exclusively, cooperatively, or redundantly.
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